WO1997024339A1 - Derives de tetrazole et medicaments les contenant a titre d'ingredients actifs - Google Patents
Derives de tetrazole et medicaments les contenant a titre d'ingredients actifs Download PDFInfo
- Publication number
- WO1997024339A1 WO1997024339A1 PCT/JP1996/003801 JP9603801W WO9724339A1 WO 1997024339 A1 WO1997024339 A1 WO 1997024339A1 JP 9603801 W JP9603801 W JP 9603801W WO 9724339 A1 WO9724339 A1 WO 9724339A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino
- oxo
- pentanoic acid
- benzyloxycarbonyl
- tetrazole
- Prior art date
Links
- 150000003536 tetrazoles Chemical class 0.000 title claims abstract description 33
- 239000004480 active ingredient Substances 0.000 title claims abstract description 9
- 239000003814 drug Substances 0.000 title claims abstract description 8
- 229940079593 drug Drugs 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 223
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 54
- 150000003839 salts Chemical class 0.000 claims abstract description 54
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 27
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 22
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 20
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 20
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 20
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 9
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 1012
- -1 phenyloxy Chemical group 0.000 claims description 788
- GSYSFVSGPABNNL-UHFFFAOYSA-N methyl 2-dimethoxyphosphoryl-2-(phenylmethoxycarbonylamino)acetate Chemical group COC(=O)C(P(=O)(OC)OC)NC(=O)OCC1=CC=CC=C1 GSYSFVSGPABNNL-UHFFFAOYSA-N 0.000 claims description 158
- 239000002253 acid Substances 0.000 claims description 109
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 92
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 76
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 66
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 59
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 52
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 43
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 42
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 34
- 125000003277 amino group Chemical group 0.000 claims description 28
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 25
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 claims description 21
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims description 20
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 18
- 125000004434 sulfur atom Chemical group 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 17
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 125000005843 halogen group Chemical group 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 15
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 15
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 14
- MSMMUUXFHIRGEZ-UHFFFAOYSA-N 5-(5-benzyltetrazol-1-yl)pentanoic acid Chemical compound OC(=O)CCCCN1N=NN=C1CC1=CC=CC=C1 MSMMUUXFHIRGEZ-UHFFFAOYSA-N 0.000 claims description 13
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 13
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 12
- 150000001721 carbon Chemical group 0.000 claims description 12
- 125000004523 tetrazol-1-yl group Chemical group N1(N=NN=C1)* 0.000 claims description 11
- 125000001241 2-phenylethylthio group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])S* 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical group 0.000 claims description 10
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 9
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 claims description 9
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims description 8
- 125000003282 alkyl amino group Chemical group 0.000 claims description 8
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 8
- 125000002619 bicyclic group Chemical group 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 208000006454 hepatitis Diseases 0.000 claims description 8
- 231100000283 hepatitis Toxicity 0.000 claims description 8
- 125000002950 monocyclic group Chemical group 0.000 claims description 8
- 125000002560 nitrile group Chemical group 0.000 claims description 8
- 125000004414 alkyl thio group Chemical group 0.000 claims description 7
- 125000002837 carbocyclic group Chemical group 0.000 claims description 7
- 206010043554 thrombocytopenia Diseases 0.000 claims description 7
- 208000012124 AIDS-related disease Diseases 0.000 claims description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
- HWYHDWGGACRVEH-UHFFFAOYSA-N n-methyl-n-(4-pyrrolidin-1-ylbut-2-ynyl)acetamide Chemical compound CC(=O)N(C)CC#CCN1CCCC1 HWYHDWGGACRVEH-UHFFFAOYSA-N 0.000 claims description 6
- 229930189471 penicacid Natural products 0.000 claims description 6
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 5
- 208000035473 Communicable disease Diseases 0.000 claims description 5
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 5
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 claims description 5
- 125000000539 amino acid group Chemical group 0.000 claims description 5
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 5
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 5
- 150000004677 hydrates Chemical class 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000005977 3-phenylpropyloxy group Chemical group 0.000 claims description 4
- STYJYIWAEVHUHT-UHFFFAOYSA-N 5-[5-[(2,6-dichlorophenyl)methyl]tetrazol-1-yl]pentanoic acid Chemical compound OC(=O)CCCCN1N=NN=C1CC1=C(Cl)C=CC=C1Cl STYJYIWAEVHUHT-UHFFFAOYSA-N 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- YSJBRRILDNIWRS-UHFFFAOYSA-N NC(C(=O)O)CC(CN1N=NN=C1CC1=CC=CC=C1)=O Chemical compound NC(C(=O)O)CC(CN1N=NN=C1CC1=CC=CC=C1)=O YSJBRRILDNIWRS-UHFFFAOYSA-N 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical group C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 206010009887 colitis Diseases 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 4
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims description 3
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 claims description 3
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000005975 2-phenylethyloxy group Chemical group 0.000 claims description 3
- NDMAQUNWOYUOGS-UHFFFAOYSA-N 5-[(2,6-dichlorophenyl)methyl]-2h-tetrazole Chemical compound ClC1=CC=CC(Cl)=C1CC1=NNN=N1 NDMAQUNWOYUOGS-UHFFFAOYSA-N 0.000 claims description 3
- WVMSRFLPDONZGD-UHFFFAOYSA-N 5-[5-(2-carboxyethyl)tetrazol-2-yl]-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound N1=C(CCC(=O)O)N=NN1CC(=O)C(CC(O)=O)NC(=O)OCC1=CC=CC=C1 WVMSRFLPDONZGD-UHFFFAOYSA-N 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 claims description 3
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims description 3
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 3
- 208000036487 Arthropathies Diseases 0.000 claims description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 3
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 3
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 3
- 208000002177 Cataract Diseases 0.000 claims description 3
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 3
- 208000027932 Collagen disease Diseases 0.000 claims description 3
- 206010010356 Congenital anomaly Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 3
- 239000001263 FEMA 3042 Substances 0.000 claims description 3
- 206010016654 Fibrosis Diseases 0.000 claims description 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 3
- 102000004877 Insulin Human genes 0.000 claims description 3
- 108090001061 Insulin Proteins 0.000 claims description 3
- 208000012659 Joint disease Diseases 0.000 claims description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
- 206010028570 Myelopathy Diseases 0.000 claims description 3
- 208000009525 Myocarditis Diseases 0.000 claims description 3
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims description 3
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 3
- 206010063837 Reperfusion injury Diseases 0.000 claims description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 3
- 206010040070 Septic Shock Diseases 0.000 claims description 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 3
- 206010046798 Uterine leiomyoma Diseases 0.000 claims description 3
- 206010046851 Uveitis Diseases 0.000 claims description 3
- 201000006966 adult T-cell leukemia Diseases 0.000 claims description 3
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 3
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 3
- 125000006294 amino alkylene group Chemical group 0.000 claims description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 3
- 208000003167 cholangitis Diseases 0.000 claims description 3
- 230000007882 cirrhosis Effects 0.000 claims description 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 3
- 238000005345 coagulation Methods 0.000 claims description 3
- 230000015271 coagulation Effects 0.000 claims description 3
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 206010014599 encephalitis Diseases 0.000 claims description 3
- 206010014665 endocarditis Diseases 0.000 claims description 3
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 3
- 229940125396 insulin Drugs 0.000 claims description 3
- 125000000468 ketone group Chemical group 0.000 claims description 3
- 201000010260 leiomyoma Diseases 0.000 claims description 3
- 230000036244 malformation Effects 0.000 claims description 3
- 201000006938 muscular dystrophy Diseases 0.000 claims description 3
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 3
- 206010028417 myasthenia gravis Diseases 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 150000002825 nitriles Chemical class 0.000 claims description 3
- 125000005702 oxyalkylene group Chemical group 0.000 claims description 3
- 208000008494 pericarditis Diseases 0.000 claims description 3
- 230000000737 periodic effect Effects 0.000 claims description 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 201000008525 senile cataract Diseases 0.000 claims description 3
- 230000036303 septic shock Effects 0.000 claims description 3
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims description 3
- 235000015523 tannic acid Nutrition 0.000 claims description 3
- 229920002258 tannic acid Polymers 0.000 claims description 3
- 229940033123 tannic acid Drugs 0.000 claims description 3
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 2
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 125000004442 acylamino group Chemical group 0.000 claims description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 2
- 210000000845 cartilage Anatomy 0.000 claims description 2
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 208000023504 respiratory system disease Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 230000005951 type IV hypersensitivity Effects 0.000 claims description 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims description 2
- BQMMAOZNLWVMGB-UHFFFAOYSA-N 5-(5-benzoyltetrazol-2-yl)-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound N1=NC(C(=O)C=2C=CC=CC=2)=NN1CC(=O)C(CC(=O)O)NC(=O)OCC1=CC=CC=C1 BQMMAOZNLWVMGB-UHFFFAOYSA-N 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- HKFAKVFPSHMFSK-UHFFFAOYSA-N 3-(benzylsulfanylcarbonylamino)-5-[5-[(2,6-dichlorophenyl)methyl]tetrazol-2-yl]-4-oxopentanoic acid Chemical compound N1=NC(CC=2C(=CC=CC=2Cl)Cl)=NN1CC(=O)C(CC(=O)O)NC(=O)SCC1=CC=CC=C1 HKFAKVFPSHMFSK-UHFFFAOYSA-N 0.000 claims 1
- FBWNLKRBOHREMW-UHFFFAOYSA-N 3-[(2-bromophenyl)sulfonylamino]-5-[5-[(2,6-dichlorophenyl)methyl]tetrazol-2-yl]-4-oxopentanoic acid Chemical compound N1=NC(CC=2C(=CC=CC=2Cl)Cl)=NN1CC(=O)C(CC(=O)O)NS(=O)(=O)C1=CC=CC=C1Br FBWNLKRBOHREMW-UHFFFAOYSA-N 0.000 claims 1
- SZJZEYFVKVSQJN-UHFFFAOYSA-N 3-[(3-chlorophenyl)sulfonylamino]-5-[5-[(2,6-dichlorophenyl)methyl]tetrazol-2-yl]-4-oxopentanoic acid Chemical compound N1=NC(CC=2C(=CC=CC=2Cl)Cl)=NN1CC(=O)C(CC(=O)O)NS(=O)(=O)C1=CC=CC(Cl)=C1 SZJZEYFVKVSQJN-UHFFFAOYSA-N 0.000 claims 1
- PBZFMAOPZXRRJF-UHFFFAOYSA-N 3-[[benzyl(methyl)carbamoyl]amino]-5-[5-[(2,6-dichlorophenyl)methyl]tetrazol-1-yl]-4-oxopentanoic acid Chemical compound N1=NN=C(CC=2C(=CC=CC=2Cl)Cl)N1CC(=O)C(CC(O)=O)NC(=O)N(C)CC1=CC=CC=C1 PBZFMAOPZXRRJF-UHFFFAOYSA-N 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims 1
- ALZRITNYJVSWLA-UHFFFAOYSA-N 4-oxo-3-(phenylmethoxycarbonylamino)-5-[5-(trifluoromethyl)tetrazol-2-yl]pentanoic acid Chemical compound N1=NC(C(F)(F)F)=NN1CC(=O)C(CC(=O)O)NC(=O)OCC1=CC=CC=C1 ALZRITNYJVSWLA-UHFFFAOYSA-N 0.000 claims 1
- WZHLFABLDXLAJS-UHFFFAOYSA-N 4-oxo-3-(phenylmethoxycarbonylamino)-5-[5-[4-(trifluoromethoxy)phenyl]sulfanyltetrazol-1-yl]pentanoic acid Chemical compound N1=NN=C(SC=2C=CC(OC(F)(F)F)=CC=2)N1CC(=O)C(CC(=O)O)NC(=O)OCC1=CC=CC=C1 WZHLFABLDXLAJS-UHFFFAOYSA-N 0.000 claims 1
- KZFSKNGIBYNQMI-UHFFFAOYSA-N 5-(5-bromotetrazol-2-yl)-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound N1=NC(Br)=NN1CC(=O)C(CC(=O)O)NC(=O)OCC1=CC=CC=C1 KZFSKNGIBYNQMI-UHFFFAOYSA-N 0.000 claims 1
- XSXAWAAMHLBNNZ-UHFFFAOYSA-N 5-(5-cyclohexylsulfanyltetrazol-2-yl)-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound N1=NC(SC2CCCCC2)=NN1CC(=O)C(CC(=O)O)NC(=O)OCC1=CC=CC=C1 XSXAWAAMHLBNNZ-UHFFFAOYSA-N 0.000 claims 1
- JJRRPWBJRJAIAK-UHFFFAOYSA-N 5-(5-methoxytetrazol-2-yl)-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound N1=C(OC)N=NN1CC(=O)C(CC(O)=O)NC(=O)OCC1=CC=CC=C1 JJRRPWBJRJAIAK-UHFFFAOYSA-N 0.000 claims 1
- HOVHEGCXVSINDP-UHFFFAOYSA-N 5-[5-(2,4-dichlorophenyl)sulfanyltetrazol-2-yl]-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound N1=NC(SC=2C(=CC(Cl)=CC=2)Cl)=NN1CC(=O)C(CC(=O)O)NC(=O)OCC1=CC=CC=C1 HOVHEGCXVSINDP-UHFFFAOYSA-N 0.000 claims 1
- CJWWCGOVSRXGPU-UHFFFAOYSA-N 5-[5-(2,4-dimethylphenyl)sulfanyltetrazol-2-yl]-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound CC1=CC(C)=CC=C1SC1=NN(CC(=O)C(CC(O)=O)NC(=O)OCC=2C=CC=CC=2)N=N1 CJWWCGOVSRXGPU-UHFFFAOYSA-N 0.000 claims 1
- DAMABYOERFDGIQ-UHFFFAOYSA-N 5-[5-(2,5-dichlorophenyl)sulfanyltetrazol-1-yl]-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound N1=NN=C(SC=2C(=CC=C(Cl)C=2)Cl)N1CC(=O)C(CC(=O)O)NC(=O)OCC1=CC=CC=C1 DAMABYOERFDGIQ-UHFFFAOYSA-N 0.000 claims 1
- WAMKNXWDKREVGG-UHFFFAOYSA-N 5-[5-(2,6-dichlorophenyl)tetrazol-2-yl]-4-oxopentanoic acid Chemical compound OC(=O)CCC(=O)CN1N=NC(C=2C(=CC=CC=2Cl)Cl)=N1 WAMKNXWDKREVGG-UHFFFAOYSA-N 0.000 claims 1
- SQPMTXNZVXPYHB-UHFFFAOYSA-N 5-[5-(2-chloro-4-fluorophenyl)sulfanyltetrazol-1-yl]-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound N1=NN=C(SC=2C(=CC(F)=CC=2)Cl)N1CC(=O)C(CC(=O)O)NC(=O)OCC1=CC=CC=C1 SQPMTXNZVXPYHB-UHFFFAOYSA-N 0.000 claims 1
- SJAWLAJTUCTOFQ-UHFFFAOYSA-N 5-[5-(4-bromophenyl)sulfanyltetrazol-1-yl]-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound N1=NN=C(SC=2C=CC(Br)=CC=2)N1CC(=O)C(CC(=O)O)NC(=O)OCC1=CC=CC=C1 SJAWLAJTUCTOFQ-UHFFFAOYSA-N 0.000 claims 1
- OYRBAPASGQEYIY-UHFFFAOYSA-N 5-[5-(4-methoxyphenyl)sulfanyltetrazol-1-yl]-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound C1=CC(OC)=CC=C1SC1=NN=NN1CC(=O)C(CC(O)=O)NC(=O)OCC1=CC=CC=C1 OYRBAPASGQEYIY-UHFFFAOYSA-N 0.000 claims 1
- QZVPJSBFKMCYKS-UHFFFAOYSA-N 5-[5-(4-methylphenyl)sulfanyltetrazol-1-yl]-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound C1=CC(C)=CC=C1SC1=NN=NN1CC(=O)C(CC(O)=O)NC(=O)OCC1=CC=CC=C1 QZVPJSBFKMCYKS-UHFFFAOYSA-N 0.000 claims 1
- UCPDSTKRJHHVDH-UHFFFAOYSA-N 5-[5-(carboxymethyl)tetrazol-2-yl]-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound N1=NC(CC(O)=O)=NN1CC(=O)C(CC(=O)O)NC(=O)OCC1=CC=CC=C1 UCPDSTKRJHHVDH-UHFFFAOYSA-N 0.000 claims 1
- TYPNBGHTYOZCJH-UHFFFAOYSA-N 5-[5-(dibenzylamino)tetrazol-2-yl]-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound N1=NC(N(CC=2C=CC=CC=2)CC=2C=CC=CC=2)=NN1CC(=O)C(CC(=O)O)NC(=O)OCC1=CC=CC=C1 TYPNBGHTYOZCJH-UHFFFAOYSA-N 0.000 claims 1
- PZEWUJPJALWZMZ-UHFFFAOYSA-N 5-[5-[(2,6-dichlorophenyl)methyl]tetrazol-2-yl]-3-[(4-methoxyphenyl)sulfonylamino]-4-oxopentanoic acid Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NC(CC(O)=O)C(=O)CN1N=C(CC=2C(=CC=CC=2Cl)Cl)N=N1 PZEWUJPJALWZMZ-UHFFFAOYSA-N 0.000 claims 1
- JCBMIRJLOXOFRX-UHFFFAOYSA-N 5-[5-[(2,6-dichlorophenyl)methyl]tetrazol-2-yl]-3-[(4-methylphenyl)sulfonylamino]-4-oxopentanoic acid Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(CC(O)=O)C(=O)CN1N=C(CC=2C(=CC=CC=2Cl)Cl)N=N1 JCBMIRJLOXOFRX-UHFFFAOYSA-N 0.000 claims 1
- YMDIKKMELHDJKW-UHFFFAOYSA-N 5-[5-[(2,6-dichlorophenyl)methyl]tetrazol-2-yl]-4-oxo-3-[(2-phenoxyphenyl)sulfonylamino]pentanoic acid Chemical compound N1=NC(CC=2C(=CC=CC=2Cl)Cl)=NN1CC(=O)C(CC(=O)O)NS(=O)(=O)C1=CC=CC=C1OC1=CC=CC=C1 YMDIKKMELHDJKW-UHFFFAOYSA-N 0.000 claims 1
- PGBDEPMODWUXMD-UHFFFAOYSA-N 5-[5-[(2,6-dichlorophenyl)methyl]tetrazol-2-yl]-4-oxo-3-[2-(phenylmethoxycarbonylamino)ethylsulfonylamino]pentanoic acid Chemical compound N1=NC(CC=2C(=CC=CC=2Cl)Cl)=NN1CC(=O)C(CC(=O)O)NS(=O)(=O)CCNC(=O)OCC1=CC=CC=C1 PGBDEPMODWUXMD-UHFFFAOYSA-N 0.000 claims 1
- CFGDQNPQNIQWSV-UHFFFAOYSA-N 5-[5-[(2,6-difluorophenyl)methyl]tetrazol-1-yl]-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound N1=NN=C(CC=2C(=CC=CC=2F)F)N1CC(=O)C(CC(=O)O)NC(=O)OCC1=CC=CC=C1 CFGDQNPQNIQWSV-UHFFFAOYSA-N 0.000 claims 1
- GXEQYULOXMJDGH-UHFFFAOYSA-N 5-[5-[[4-(1h-imidazol-2-yl)phenyl]methyl]tetrazol-1-yl]-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound N1=NN=C(CC=2C=CC(=CC=2)C=2NC=CN=2)N1CC(=O)C(CC(=O)O)NC(=O)OCC1=CC=CC=C1 GXEQYULOXMJDGH-UHFFFAOYSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 101150047265 COR2 gene Proteins 0.000 claims 1
- 101100134922 Gallus gallus COR5 gene Proteins 0.000 claims 1
- 241001024304 Mino Species 0.000 claims 1
- 101100062121 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cyc-1 gene Proteins 0.000 claims 1
- 101100467189 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) QCR2 gene Proteins 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 13
- 102000004190 Enzymes Human genes 0.000 abstract description 10
- 108090000790 Enzymes Proteins 0.000 abstract description 10
- 230000002265 prevention Effects 0.000 abstract description 3
- 125000004450 alkenylene group Chemical group 0.000 abstract description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 abstract 1
- 102000003777 Interleukin-1 beta Human genes 0.000 abstract 1
- 108090000193 Interleukin-1 beta Proteins 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 909
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 474
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 398
- 238000004809 thin layer chromatography Methods 0.000 description 393
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 336
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 330
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 152
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 117
- 239000004744 fabric Substances 0.000 description 109
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 76
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 64
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 61
- 229910052739 hydrogen Inorganic materials 0.000 description 61
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 60
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 48
- 239000000243 solution Substances 0.000 description 45
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 42
- 239000011541 reaction mixture Substances 0.000 description 41
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 37
- 238000000034 method Methods 0.000 description 35
- 239000000203 mixture Substances 0.000 description 33
- 125000001424 substituent group Chemical group 0.000 description 32
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 29
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 28
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 25
- 239000001257 hydrogen Substances 0.000 description 22
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- 239000007864 aqueous solution Substances 0.000 description 21
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 19
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 19
- 125000003118 aryl group Chemical group 0.000 description 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 17
- 239000003960 organic solvent Substances 0.000 description 17
- 229920006395 saturated elastomer Polymers 0.000 description 17
- 102000000589 Interleukin-1 Human genes 0.000 description 15
- 108010002352 Interleukin-1 Proteins 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- 125000004494 ethyl ester group Chemical group 0.000 description 14
- 125000001072 heteroaryl group Chemical group 0.000 description 14
- 125000006239 protecting group Chemical group 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 14
- 239000000284 extract Substances 0.000 description 13
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 11
- 150000002431 hydrogen Chemical group 0.000 description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 9
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 9
- 238000010898 silica gel chromatography Methods 0.000 description 9
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 8
- 102000003815 Interleukin-11 Human genes 0.000 description 8
- 125000004185 ester group Chemical group 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 150000004820 halides Chemical class 0.000 description 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 6
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 239000012298 atmosphere Substances 0.000 description 6
- 238000007327 hydrogenolysis reaction Methods 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- ORLCYMQZIPSODD-UHFFFAOYSA-N 1-chloro-2-[chloro(2,2,2-trichloroethoxy)phosphoryl]oxybenzene Chemical group ClC1=CC=CC=C1OP(Cl)(=O)OCC(Cl)(Cl)Cl ORLCYMQZIPSODD-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 229960005261 aspartic acid Drugs 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 239000003701 inert diluent Substances 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 238000006722 reduction reaction Methods 0.000 description 5
- 150000003512 tertiary amines Chemical class 0.000 description 5
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- ICMAFTSLXCXHRK-UHFFFAOYSA-N Ethyl pentanoate Chemical compound CCCCC(=O)OCC ICMAFTSLXCXHRK-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 238000007112 amidation reaction Methods 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000012300 argon atmosphere Substances 0.000 description 4
- 235000003704 aspartic acid Nutrition 0.000 description 4
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 4
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 4
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000008247 solid mixture Substances 0.000 description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 4
- 229910052727 yttrium Inorganic materials 0.000 description 4
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- HHDRWGJJZGJSGZ-UHFFFAOYSA-N 5-benzyl-2h-tetrazole Chemical compound C=1C=CC=CC=1CC=1N=NNN=1 HHDRWGJJZGJSGZ-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 101150065749 Churc1 gene Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100038239 Protein Churchill Human genes 0.000 description 3
- 125000002723 alicyclic group Chemical group 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- KNFPLMFTXFVFPA-UHFFFAOYSA-N lithium;bis(2-methylpropyl)azanide Chemical compound CC(C)CN([Li])CC(C)C KNFPLMFTXFVFPA-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- SCSLUABEVMLYEA-UHFFFAOYSA-N tert-butyl pentanoate Chemical compound CCCCC(=O)OC(C)(C)C SCSLUABEVMLYEA-UHFFFAOYSA-N 0.000 description 3
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- JQIZHNLEFQMDCQ-UHFFFAOYSA-N 1,2,3,4-tetrahydropyridazine Chemical compound C1CC=CNN1 JQIZHNLEFQMDCQ-UHFFFAOYSA-N 0.000 description 2
- OTPDWCMLUKMQNO-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrimidine Chemical compound C1NCC=CN1 OTPDWCMLUKMQNO-UHFFFAOYSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- FHGWEHGZBUBQKL-UHFFFAOYSA-N 1,2-benzothiazepine Chemical compound S1N=CC=CC2=CC=CC=C12 FHGWEHGZBUBQKL-UHFFFAOYSA-N 0.000 description 2
- XXBQLHATYQHJQC-UHFFFAOYSA-N 1,2-dihydroquinoxaline Chemical compound C1=CC=C2N=CCNC2=C1 XXBQLHATYQHJQC-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 2
- YDDBBPWOTOHIPJ-UHFFFAOYSA-N 2-amino-5-[5-[(2,6-dichlorophenyl)methyl]tetrazol-1-yl]-4-oxopentanoic acid Chemical compound NC(C(=O)O)CC(CN1N=NN=C1CC1=C(C=CC=C1Cl)Cl)=O YDDBBPWOTOHIPJ-UHFFFAOYSA-N 0.000 description 2
- YZBOVSFWWNVKRJ-UHFFFAOYSA-M 2-butoxycarbonylbenzoate Chemical compound CCCCOC(=O)C1=CC=CC=C1C([O-])=O YZBOVSFWWNVKRJ-UHFFFAOYSA-M 0.000 description 2
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 2
- HOGWCFUVPSZIAA-UHFFFAOYSA-N 3-(benzenesulfonamido)-5-[5-[(2,6-dichlorophenyl)methyl]tetrazol-1-yl]-4-oxopentanoic acid Chemical compound N1=NN=C(CC=2C(=CC=CC=2Cl)Cl)N1CC(=O)C(CC(=O)O)NS(=O)(=O)C1=CC=CC=C1 HOGWCFUVPSZIAA-UHFFFAOYSA-N 0.000 description 2
- NRCDFCANBKAOKL-UHFFFAOYSA-N 3-amino-5-[5-[(2,6-dichlorophenyl)methyl]tetrazol-2-yl]-4-oxopentanoic acid Chemical compound OC(=O)CC(N)C(=O)CN1N=NC(CC=2C(=CC=CC=2Cl)Cl)=N1 NRCDFCANBKAOKL-UHFFFAOYSA-N 0.000 description 2
- HHXJBNQSUADDBU-UHFFFAOYSA-N 5-(5-naphthalen-1-ylsulfanyltetrazol-1-yl)-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound N1=NN=C(SC=2C3=CC=CC=C3C=CC=2)N1CC(=O)C(CC(=O)O)NC(=O)OCC1=CC=CC=C1 HHXJBNQSUADDBU-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- OKJADYKTJJGKDX-UHFFFAOYSA-N Butyl pentanoate Chemical compound CCCCOC(=O)CCCC OKJADYKTJJGKDX-UHFFFAOYSA-N 0.000 description 2
- 101150041968 CDC13 gene Proteins 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 235000003332 Ilex aquifolium Nutrition 0.000 description 2
- 241000209027 Ilex aquifolium Species 0.000 description 2
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 2
- 102000004553 Interleukin-11 Receptors Human genes 0.000 description 2
- 108010017521 Interleukin-11 Receptors Proteins 0.000 description 2
- 102000000646 Interleukin-3 Human genes 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- ZSWFCLXCOIISFI-UHFFFAOYSA-N cyclopentadiene Chemical compound C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000010931 ester hydrolysis Methods 0.000 description 2
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 2
- KIWBPDUYBMNFTB-UHFFFAOYSA-M ethyl sulfate Chemical compound CCOS([O-])(=O)=O KIWBPDUYBMNFTB-UHFFFAOYSA-M 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 125000004475 heteroaralkyl group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical compound O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 description 2
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 2
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 235000004400 serine Nutrition 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000005694 sulfonylation reaction Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 235000008521 threonine Nutrition 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- CZPRKINNVBONSF-UHFFFAOYSA-M zinc;dioxido(oxo)phosphanium Chemical compound [Zn+2].[O-][P+]([O-])=O CZPRKINNVBONSF-UHFFFAOYSA-M 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- ZCZVGQCBSJLDDS-UHFFFAOYSA-N 1,2,3,4-tetrahydro-1,8-naphthyridine Chemical compound C1=CC=C2CCCNC2=N1 ZCZVGQCBSJLDDS-UHFFFAOYSA-N 0.000 description 1
- STIWEDICJHIFJT-UHFFFAOYSA-N 1,2,3,4-tetrahydrophthalazine Chemical compound C1=CC=C2CNNCC2=C1 STIWEDICJHIFJT-UHFFFAOYSA-N 0.000 description 1
- FNQJDLTXOVEEFB-UHFFFAOYSA-N 1,2,3-benzothiadiazole Chemical compound C1=CC=C2SN=NC2=C1 FNQJDLTXOVEEFB-UHFFFAOYSA-N 0.000 description 1
- ZCXLTWVZYXBHJS-UHFFFAOYSA-N 1,2-benzoxazepine Chemical compound O1N=CC=CC2=CC=CC=C12 ZCXLTWVZYXBHJS-UHFFFAOYSA-N 0.000 description 1
- XEYKWYIXHMEQGM-UHFFFAOYSA-N 1,2-dihydro-1,8-naphthyridine Chemical compound C1=CC=C2C=CCNC2=N1 XEYKWYIXHMEQGM-UHFFFAOYSA-N 0.000 description 1
- IOEPOEDBBPRAEI-UHFFFAOYSA-N 1,2-dihydroisoquinoline Chemical compound C1=CC=C2CNC=CC2=C1 IOEPOEDBBPRAEI-UHFFFAOYSA-N 0.000 description 1
- IRFSXVIRXMYULF-UHFFFAOYSA-N 1,2-dihydroquinoline Chemical compound C1=CC=C2C=CCNC2=C1 IRFSXVIRXMYULF-UHFFFAOYSA-N 0.000 description 1
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 1
- CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- DQFQCHIDRBIESA-UHFFFAOYSA-N 1-benzazepine Chemical compound N1C=CC=CC2=CC=CC=C12 DQFQCHIDRBIESA-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- AWBOSXFRPFZLOP-UHFFFAOYSA-N 2,1,3-benzoxadiazole Chemical compound C1=CC=CC2=NON=C21 AWBOSXFRPFZLOP-UHFFFAOYSA-N 0.000 description 1
- DNZWAKVIOXCEHH-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1-benzofuran Chemical compound C1CCCC2OCCC21 DNZWAKVIOXCEHH-UHFFFAOYSA-N 0.000 description 1
- LVJPACZOEKXFAY-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-indazole Chemical compound C1CCCC2CNNC21 LVJPACZOEKXFAY-UHFFFAOYSA-N 0.000 description 1
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 description 1
- YTQQIHUQLOZOJI-UHFFFAOYSA-N 2,3-dihydro-1,2-thiazole Chemical compound C1NSC=C1 YTQQIHUQLOZOJI-UHFFFAOYSA-N 0.000 description 1
- HRCMXYXVAWHBTH-UHFFFAOYSA-N 2,3-dihydro-1,3-benzoxazole Chemical compound C1=CC=C2OCNC2=C1 HRCMXYXVAWHBTH-UHFFFAOYSA-N 0.000 description 1
- OYJGEOAXBALSMM-UHFFFAOYSA-N 2,3-dihydro-1,3-thiazole Chemical compound C1NC=CS1 OYJGEOAXBALSMM-UHFFFAOYSA-N 0.000 description 1
- YJUFGFXVASPYFQ-UHFFFAOYSA-N 2,3-dihydro-1-benzothiophene Chemical compound C1=CC=C2SCCC2=C1 YJUFGFXVASPYFQ-UHFFFAOYSA-N 0.000 description 1
- QDKGOMZIPXGDDJ-UHFFFAOYSA-N 2,3-dihydro-1h-indazole Chemical compound C1=CC=C2CNNC2=C1 QDKGOMZIPXGDDJ-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- HFZWRUODUSTPEG-UHFFFAOYSA-N 2,4-dichlorophenol Chemical compound OC1=CC=C(Cl)C=C1Cl HFZWRUODUSTPEG-UHFFFAOYSA-N 0.000 description 1
- 125000004098 2,6-dichlorobenzoyl group Chemical group O=C([*])C1=C(Cl)C([H])=C([H])C([H])=C1Cl 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- LYTMVABTDYMBQK-UHFFFAOYSA-N 2-benzothiophene Chemical compound C1=CC=CC2=CSC=C21 LYTMVABTDYMBQK-UHFFFAOYSA-N 0.000 description 1
- ZNPNOVHKCAAQCG-UHFFFAOYSA-N 2-chloro-1-methylpyridin-1-ium Chemical compound C[N+]1=CC=CC=C1Cl ZNPNOVHKCAAQCG-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- UMZCLZPXPCNKML-UHFFFAOYSA-N 2h-imidazo[4,5-d][1,3]thiazole Chemical group C1=NC2=NCSC2=N1 UMZCLZPXPCNKML-UHFFFAOYSA-N 0.000 description 1
- DIJIKOOCYZSSRK-UHFFFAOYSA-N 2h-thiadiazepino[6,7-b]indole Chemical compound C1=NNSC2=C(C=CC=C3)C3=NC2=C1 DIJIKOOCYZSSRK-UHFFFAOYSA-N 0.000 description 1
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 1
- WGTASENVNYJZBK-UHFFFAOYSA-N 3,4,5-trimethoxyamphetamine Chemical compound COC1=CC(CC(C)N)=CC(OC)=C1OC WGTASENVNYJZBK-UHFFFAOYSA-N 0.000 description 1
- ATVJJNGVPSKBGO-UHFFFAOYSA-N 3,4-dihydro-2h-thiopyran Chemical compound C1CSC=CC1 ATVJJNGVPSKBGO-UHFFFAOYSA-N 0.000 description 1
- ZOJWRVVTKFOPJH-UHFFFAOYSA-N 3-(2,1,3-benzothiadiazol-4-ylsulfonylamino)-5-[5-[(2,6-dichlorophenyl)methyl]tetrazol-2-yl]-4-oxopentanoic acid Chemical compound C=1C=CC2=NSN=C2C=1S(=O)(=O)NC(CC(=O)O)C(=O)CN(N=1)N=NC=1CC1=C(Cl)C=CC=C1Cl ZOJWRVVTKFOPJH-UHFFFAOYSA-N 0.000 description 1
- YNJSNEKCXVFDKW-UHFFFAOYSA-N 3-(5-amino-1h-indol-3-yl)-2-azaniumylpropanoate Chemical compound C1=C(N)C=C2C(CC(N)C(O)=O)=CNC2=C1 YNJSNEKCXVFDKW-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ZUALSLMAEXBXHY-UHFFFAOYSA-N 4-oxo-3-(phenylmethoxycarbonylamino)-5-(5-phenylsulfanyltetrazol-1-yl)pentanoic acid Chemical compound N1=NN=C(SC=2C=CC=CC=2)N1CC(=O)C(CC(=O)O)NC(=O)OCC1=CC=CC=C1 ZUALSLMAEXBXHY-UHFFFAOYSA-N 0.000 description 1
- NAFWUBVQWFKQSB-UHFFFAOYSA-N 4-oxo-3-(phenylmethoxycarbonylamino)-5-[5-[4-[(2,2,2-trifluoroacetyl)amino]phenyl]sulfanyltetrazol-2-yl]pentanoic acid Chemical compound N1=NC(SC=2C=CC(NC(=O)C(F)(F)F)=CC=2)=NN1CC(=O)C(CC(=O)O)NC(=O)OCC1=CC=CC=C1 NAFWUBVQWFKQSB-UHFFFAOYSA-N 0.000 description 1
- ZLROLDJLLNTTSI-UHFFFAOYSA-N 4-oxo-5-[5-(2-phenylethenyl)tetrazol-2-yl]-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound N1=NC(C=CC=2C=CC=CC=2)=NN1CC(=O)C(CC(=O)O)NC(=O)OCC1=CC=CC=C1 ZLROLDJLLNTTSI-UHFFFAOYSA-N 0.000 description 1
- YEZADZMMVHWFIY-UHFFFAOYSA-N 4-tert-butylbenzenesulfonyl chloride Chemical compound CC(C)(C)C1=CC=C(S(Cl)(=O)=O)C=C1 YEZADZMMVHWFIY-UHFFFAOYSA-N 0.000 description 1
- UHYGCMNTYAEAHI-UHFFFAOYSA-N 5-(2-phenylethenyl)-2h-tetrazole Chemical compound N1=NNN=C1C=CC1=CC=CC=C1 UHYGCMNTYAEAHI-UHFFFAOYSA-N 0.000 description 1
- AFVBZUWBUBBTKS-UHFFFAOYSA-N 5-(2-phenylethyl)-2h-tetrazole Chemical compound N1=NNN=C1CCC1=CC=CC=C1 AFVBZUWBUBBTKS-UHFFFAOYSA-N 0.000 description 1
- MDZNENQZZRVEDI-UHFFFAOYSA-N 5-(4-methylphenoxy)-2h-tetrazole Chemical compound C1=CC(C)=CC=C1OC1=NNN=N1 MDZNENQZZRVEDI-UHFFFAOYSA-N 0.000 description 1
- FGAJTWJWHRUMSO-UHFFFAOYSA-N 5-(5-benzhydryltetrazol-1-yl)-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound N1=NN=C(C(C=2C=CC=CC=2)C=2C=CC=CC=2)N1CC(=O)C(CC(=O)O)NC(=O)OCC1=CC=CC=C1 FGAJTWJWHRUMSO-UHFFFAOYSA-N 0.000 description 1
- FZDGDDQQHUHKER-UHFFFAOYSA-N 5-(5-benzyltetrazol-2-yl)-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound N1=NC(CC=2C=CC=CC=2)=NN1CC(=O)C(CC(=O)O)NC(=O)OCC1=CC=CC=C1 FZDGDDQQHUHKER-UHFFFAOYSA-N 0.000 description 1
- KYWWODIQXBJSAG-UHFFFAOYSA-N 5-(5-ethylsulfanyltetrazol-1-yl)-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound CCSC1=NN=NN1CC(=O)C(CC(O)=O)NC(=O)OCC1=CC=CC=C1 KYWWODIQXBJSAG-UHFFFAOYSA-N 0.000 description 1
- OTHYRAFKZSHSJX-UHFFFAOYSA-N 5-[5-(1h-benzimidazol-2-ylmethyl)tetrazol-2-yl]-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound N1=NC(CC=2NC3=CC=CC=C3N=2)=NN1CC(=O)C(CC(=O)O)NC(=O)OCC1=CC=CC=C1 OTHYRAFKZSHSJX-UHFFFAOYSA-N 0.000 description 1
- YYMCURQMLFEYKJ-UHFFFAOYSA-N 5-[5-(1h-imidazol-5-ylmethyl)tetrazol-2-yl]-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound N1=NC(CC=2NC=NC=2)=NN1CC(=O)C(CC(=O)O)NC(=O)OCC1=CC=CC=C1 YYMCURQMLFEYKJ-UHFFFAOYSA-N 0.000 description 1
- WIFZBWPAGZUBCK-UHFFFAOYSA-N 5-[5-(2,6-dimethylphenyl)sulfanyltetrazol-1-yl]-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound CC1=CC=CC(C)=C1SC1=NN=NN1CC(=O)C(CC(O)=O)NC(=O)OCC1=CC=CC=C1 WIFZBWPAGZUBCK-UHFFFAOYSA-N 0.000 description 1
- KEYRVEDVIZXSOV-UHFFFAOYSA-N 5-[5-(2,6-dimethylphenyl)sulfanyltetrazol-2-yl]-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound CC1=CC=CC(C)=C1SC1=NN(CC(=O)C(CC(O)=O)NC(=O)OCC=2C=CC=CC=2)N=N1 KEYRVEDVIZXSOV-UHFFFAOYSA-N 0.000 description 1
- IFPICWPQTUJDGD-UHFFFAOYSA-N 5-[5-(2-methoxyphenyl)sulfanyltetrazol-2-yl]-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound COC1=CC=CC=C1SC1=NN(CC(=O)C(CC(O)=O)NC(=O)OCC=2C=CC=CC=2)N=N1 IFPICWPQTUJDGD-UHFFFAOYSA-N 0.000 description 1
- UFFNIEKUPOTAOH-UHFFFAOYSA-N 5-[5-(4-aminophenyl)sulfanyltetrazol-2-yl]-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound C1=CC(N)=CC=C1SC1=NN(CC(=O)C(CC(O)=O)NC(=O)OCC=2C=CC=CC=2)N=N1 UFFNIEKUPOTAOH-UHFFFAOYSA-N 0.000 description 1
- KSAVSXXCJDPMGM-UHFFFAOYSA-N 5-[5-(4-methoxyphenyl)sulfanyltetrazol-2-yl]-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound C1=CC(OC)=CC=C1SC1=NN(CC(=O)C(CC(O)=O)NC(=O)OCC=2C=CC=CC=2)N=N1 KSAVSXXCJDPMGM-UHFFFAOYSA-N 0.000 description 1
- OADLUOVTJJYJJU-UHFFFAOYSA-N 5-[5-(cyclohexylmethyl)tetrazol-1-yl]-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound N1=NN=C(CC2CCCCC2)N1CC(=O)C(CC(=O)O)NC(=O)OCC1=CC=CC=C1 OADLUOVTJJYJJU-UHFFFAOYSA-N 0.000 description 1
- KFEPVGCHKRVHFD-UHFFFAOYSA-N 5-[5-[(2,6-dichlorophenyl)methyl]tetrazol-1-yl]-4-oxo-3-[(4-propan-2-ylphenyl)sulfonylamino]pentanoic acid Chemical compound C1=CC(C(C)C)=CC=C1S(=O)(=O)NC(CC(O)=O)C(=O)CN1C(CC=2C(=CC=CC=2Cl)Cl)=NN=N1 KFEPVGCHKRVHFD-UHFFFAOYSA-N 0.000 description 1
- KMDRYJNOMQBVGQ-UHFFFAOYSA-N 5-[5-[(2,6-difluorophenyl)methyl]tetrazol-2-yl]-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound N1=NC(CC=2C(=CC=CC=2F)F)=NN1CC(=O)C(CC(=O)O)NC(=O)OCC1=CC=CC=C1 KMDRYJNOMQBVGQ-UHFFFAOYSA-N 0.000 description 1
- ARMICSVBMPDZOL-UHFFFAOYSA-N 5-[5-[(2,6-dimethylphenyl)methyl]tetrazol-2-yl]-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound CC1=CC=CC(C)=C1CC1=NN(CC(=O)C(CC(O)=O)NC(=O)OCC=2C=CC=CC=2)N=N1 ARMICSVBMPDZOL-UHFFFAOYSA-N 0.000 description 1
- SWNTURKTDKMYJN-UHFFFAOYSA-N 5-[5-[(4-chlorophenyl)sulfinylmethyl]tetrazol-1-yl]-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound N1=NN=C(CS(=O)C=2C=CC(Cl)=CC=2)N1CC(=O)C(CC(=O)O)NC(=O)OCC1=CC=CC=C1 SWNTURKTDKMYJN-UHFFFAOYSA-N 0.000 description 1
- FXWYIELDSUXTPK-UHFFFAOYSA-N 5-[5-[(4-chlorophenyl)sulfonylmethyl]tetrazol-2-yl]-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound N1=NC(CS(=O)(=O)C=2C=CC(Cl)=CC=2)=NN1CC(=O)C(CC(=O)O)NC(=O)OCC1=CC=CC=C1 FXWYIELDSUXTPK-UHFFFAOYSA-N 0.000 description 1
- JJUAADIEZXORRT-UHFFFAOYSA-N 5-[5-[2-(dimethylamino)ethyl]tetrazol-2-yl]-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound N1=C(CCN(C)C)N=NN1CC(=O)C(CC(O)=O)NC(=O)OCC1=CC=CC=C1 JJUAADIEZXORRT-UHFFFAOYSA-N 0.000 description 1
- LCYCRUYNFPZYBW-UHFFFAOYSA-N 5-[5-[4-(dimethylamino)-2,6-dimethylphenyl]sulfanyltetrazol-2-yl]-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound CC1=CC(N(C)C)=CC(C)=C1SC1=NN(CC(=O)C(CC(O)=O)NC(=O)OCC=2C=CC=CC=2)N=N1 LCYCRUYNFPZYBW-UHFFFAOYSA-N 0.000 description 1
- ZWFJRXDXXCBOAC-UHFFFAOYSA-N 5-methoxy-2h-tetrazole Chemical compound COC=1N=NNN=1 ZWFJRXDXXCBOAC-UHFFFAOYSA-N 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000005964 Acibenzolar-S-methyl Substances 0.000 description 1
- 101100083214 Arabidopsis thaliana PHL6 gene Proteins 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 241000305772 Chionis Species 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 206010072268 Drug-induced liver injury Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000609789 Kobus vardonii Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- SLMOHEILFDUCLG-UHFFFAOYSA-N OC(=O)C(N)CC(=O)CN1N=NC(C(F)(F)F)=N1 Chemical compound OC(=O)C(N)CC(=O)CN1N=NC(C(F)(F)F)=N1 SLMOHEILFDUCLG-UHFFFAOYSA-N 0.000 description 1
- GFRROZIJVHUSKZ-FXGMSQOLSA-N OS I Natural products C[C@@H]1O[C@@H](O[C@H]2[C@@H](O)[C@@H](CO)O[C@@H](OC[C@@H](O)[C@@H](O)[C@@H](O)CO)[C@@H]2NC(=O)C)[C@H](O)[C@H](O)[C@H]1O GFRROZIJVHUSKZ-FXGMSQOLSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- JZFICWYCTCCINF-UHFFFAOYSA-N Thiadiazin Chemical compound S=C1SC(C)NC(C)N1CCN1C(=S)SC(C)NC1C JZFICWYCTCCINF-UHFFFAOYSA-N 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 108010039825 acetyl-tyrosyl-valyl-alanyl-aspartyl-7-amino-4-methylcoumarinamide Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 125000004682 aminothiocarbonyl group Chemical group NC(=S)* 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000004658 aryl carbonyl amino group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- FZIZEIAMIREUTN-UHFFFAOYSA-N azane;cerium(3+) Chemical compound N.[Ce+3] FZIZEIAMIREUTN-UHFFFAOYSA-N 0.000 description 1
- 150000001538 azepines Chemical class 0.000 description 1
- KDDCNSWPVMLDHI-UHFFFAOYSA-N azepino[3,2-b]indole Chemical compound C1=CC=CN=C2C3=CC=CC=C3N=C21 KDDCNSWPVMLDHI-UHFFFAOYSA-N 0.000 description 1
- OSJRGDBEYARHLX-UHFFFAOYSA-N azido(trimethyl)stannane Chemical compound [N-]=[N+]=[N-].C[Sn+](C)C OSJRGDBEYARHLX-UHFFFAOYSA-N 0.000 description 1
- 125000005604 azodicarboxylate group Chemical group 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 239000002585 base Chemical group 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- VALPXRNQZYGXPS-UHFFFAOYSA-N benzyl pyrrolidine-1-carboxylate Chemical compound C1CCCN1C(=O)OCC1=CC=CC=C1 VALPXRNQZYGXPS-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- ANUZKYYBDVLEEI-UHFFFAOYSA-N butane;hexane;lithium Chemical compound [Li]CCCC.CCCCCC ANUZKYYBDVLEEI-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- JETFNRIIPBNRAT-UHFFFAOYSA-N butylsulfanylbenzene Chemical group CCCCSC1=CC=CC=C1 JETFNRIIPBNRAT-UHFFFAOYSA-N 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 125000002576 diazepinyl group Chemical class N1N=C(C=CC=C1)* 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- DENRZWYUOJLTMF-UHFFFAOYSA-N diethyl sulfate Chemical compound CCOS(=O)(=O)OCC DENRZWYUOJLTMF-UHFFFAOYSA-N 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 201000008865 drug-induced hepatitis Diseases 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- NAOHMNNTUFFTBF-UHFFFAOYSA-N ethyl 2-(2h-tetrazol-5-yl)acetate Chemical compound CCOC(=O)CC=1N=NNN=1 NAOHMNNTUFFTBF-UHFFFAOYSA-N 0.000 description 1
- SYPOTYKYMINVFG-UHFFFAOYSA-N ethyl 3-amino-5-[5-[(2,6-dichlorophenyl)methyl]tetrazol-1-yl]-4-oxopentanoate Chemical compound CCOC(=O)CC(N)C(=O)CN1N=NN=C1CC1=C(Cl)C=CC=C1Cl SYPOTYKYMINVFG-UHFFFAOYSA-N 0.000 description 1
- WFCLYEAZTHWNEH-UHFFFAOYSA-N ethylthiocyanate Chemical compound CCSC#N WFCLYEAZTHWNEH-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 150000002545 isoxazoles Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- AJUXDFHPVZQOGF-UHFFFAOYSA-N n,n-dimethyl-1-naphthylamine Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1 AJUXDFHPVZQOGF-UHFFFAOYSA-N 0.000 description 1
- XUYRDKGAGMTGRC-UHFFFAOYSA-N n,n-dimethyl-2h-tetrazol-5-amine Chemical compound CN(C)C=1N=NNN=1 XUYRDKGAGMTGRC-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical group C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- RYDICHIKLKVOEJ-UHFFFAOYSA-N oxadiazepine Chemical compound O1C=CC=CN=N1 RYDICHIKLKVOEJ-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 150000000221 oxazepines Chemical class 0.000 description 1
- 150000004893 oxazines Chemical class 0.000 description 1
- 125000002971 oxazolyl group Chemical class 0.000 description 1
- ATYBXHSAIOKLMG-UHFFFAOYSA-N oxepin Chemical compound O1C=CC=CC=C1 ATYBXHSAIOKLMG-UHFFFAOYSA-N 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 125000005704 oxymethylene group Chemical group [H]C([H])([*:2])O[*:1] 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- GUVXZFRDPCKWEM-UHFFFAOYSA-N pentalene Chemical compound C1=CC2=CC=CC2=C1 GUVXZFRDPCKWEM-UHFFFAOYSA-N 0.000 description 1
- GODHIFXMNKQHEI-UHFFFAOYSA-N pentanoic acid;hydrochloride Chemical compound Cl.CCCCC(O)=O GODHIFXMNKQHEI-UHFFFAOYSA-N 0.000 description 1
- 150000005603 pentanoic acids Chemical class 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 201000004240 prostatic hypertrophy Diseases 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000004309 pyranyl group Chemical class O1C(C=CC=C1)* 0.000 description 1
- 150000003216 pyrazines Chemical class 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 150000004892 pyridazines Chemical class 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003461 sulfonyl halides Chemical class 0.000 description 1
- 230000006103 sulfonylation Effects 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- BXVYJQULAWJPSR-UHFFFAOYSA-N thiadiazepine Chemical compound S1C=CC=CN=N1 BXVYJQULAWJPSR-UHFFFAOYSA-N 0.000 description 1
- 150000004873 thianes Chemical class 0.000 description 1
- NYERMPLPURRVGM-UHFFFAOYSA-N thiazepine Chemical compound S1C=CC=CC=N1 NYERMPLPURRVGM-UHFFFAOYSA-N 0.000 description 1
- 150000003557 thiazoles Chemical class 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 150000003577 thiophenes Chemical class 0.000 description 1
- 150000004882 thiopyrans Chemical class 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- YONPGGFAJWQGJC-UHFFFAOYSA-K titanium(iii) chloride Chemical compound Cl[Ti](Cl)Cl YONPGGFAJWQGJC-UHFFFAOYSA-K 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000000169 tricyclic heterocycle group Chemical group 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to tetrazole derivatives.
- Interleukin-1 General formula (I) having 3 converting enzyme inhibitory activity
- Interleukin-1 is directly or indirectly involved in the immune response, inflammatory response, hematopoietic response, and regulation of neuroendocrine function, and plays a central role in biological control. This is the site power in.
- ICE Invertase
- IL-1 / 3 precursor between Asp116ZA1a117 converts it into a 17 kd active IL-11 mature form.
- IL-11 /? Activated by ICE is released extracellularly, binds to IL-11 receptor, and causes various diseases (see The New England Journal of Medicine, 32S, 106 (1993)). .
- the conditions in which ICE inhibitors are useful are not particularly limited and include, for example, autoimmune diseases including insulin-dependent (type I) diabetes and multiple sclerosis, and immunity such as acute and delayed type hypersensitivity.
- ICE or a similar cysteine protease plays an important role in the mechanism of cell death, including apoptosis.
- diseases related to apoptosis for example, infectious diseases, reduction or enhancement of immune function and brain function, or tumors.
- HIV or HTLV-1 related diseases such as AIDS, ARC (AIDS-related disease), adult T-cell leukemia, ciliary cell leukemia, myelopathy, respiratory disorders, arthropathy, uveitis, etc.
- virus-related diseases such as hepatitis C, cancer, collagen diseases such as systemic erythematosus and rheumatoid arthritis, ulcerative colitis, Siegren's syndrome, primary biliary cirrhosis, and idiopathic thrombocytopenic purpura
- Autoimmunity Autoimmune diseases such as hemolytic anemia, myasthenia gravis, insulin-dependent (type I) diabetes, myelodysplastic syndrome, periodic thrombocytopenia, aplastic anemia, idiopathic thrombocytopenia, and generalized intravascular disease
- diseases associated with thrombocytopenia such as coagulation, viral or drug-induced hepatitis C and A, B, and F, liver diseases such as cirrhosis, dementia such as Alzheimer's disease and Alzheimer's senile dementia , Cerebrovascular disorders, neurodegenerative diseases, adult respiratory distress syndrome, infectious diseases, benign prostatic hyperplasia, uterine fibroids, bron
- Aryl C1-6 alkyl (where the aryl group is phenyl, naphthyl, pyridyl, furyl, chenyl, thiazolyl, isothiazolyl, imidazolyl, benzimidazolyl, pyrazinyl, pyrimidyl, quinolinyl, isoquinolinyl, benzofuryl, benzofuryl, benzofuryl, benzofuryl , Indolyl, and brinylisoxazolyl.) And mono-substituted and di-substituted forms of this aryl (where the substituents are C1-6 alkyl, halogen, hydroxy, C1-6 alkyl carboxy) ) Represents;
- aryl C1-6 alkyl or aryl C1-6 alkyl substituted as defined above (where aryl is C1-6 alkyl, halogen, hydroxyl, C1-6 alkylcarbonyl, etc. May be mono- or di-substituted.
- R 4X and R 5X represent hydrogen, hydroxyl and the like
- aryl C1-6 alkyl (where alkyl is substituted by hydrogen, oxo, C1-3 alkyl, etc., aryl is as defined above and the aryl is monosubstituted or disubstituted) Substituted, the substituents being C1_6 alkyl, halogen, hydroxyl, C1_6 alkylcarbonyl, etc.),
- arylaminocarbonyl C 1-6 alkyl or arylcarbonylamino C 1-6 alkyl where aryl is as defined above and the aryl is mono- or di-substituted and the substituent Is C1-6 alkyl, halogen, hydroxyl, C1-6 alkyl carbonyl, etc.
- aryl C1-6 alkylaminocarbonyl C1-6 alkyl or aryl C1-6 alkylcarbonylamino C1-6 alkyl (where aryl is as defined above; The aryl is mono-substituted or di-substituted, and the substituent is C1-6 alkyl, halogen, hydroxyl, C1-6 alkylcarbonyl, etc.).
- AA 1X represents a single bond or the like; AA 2X is a single bond, or
- AA 3X is a single bond
- aryl C1-6 alkyl (where aryl is as defined above, wherein the aryl is mono- or disubstituted and the substituents are C1-6 alkyl, halogen, hydroxyl , Cl-6 alkylcarbonyl, etc.). ).
- R Y represents hydrogen, an amino protecting group, or optionally substituted benzyloxy
- ⁇ 0 represents 0 or 1
- ⁇ 1 ⁇ is Val, Leu, Ala, Ile or Trimethylsilyl A 1 a Represents;
- a 2Y represents Ph e or Tyr
- ring ⁇ may be optionally substituted by hydroxy or C 1-4 alkoxy
- ring ⁇ represents a divalent group represented by the following formula:
- a 4Y is a direct bond or 1 N-1 CH-1 CO—
- R 1Y represents hydrogen or C 1-4 alkyl, and Y 1Y represents a residue bound to one carbon atom of one amino acid which may be optionally protected.
- ⁇ 1 ⁇ represents the above definition, and R 1Y and R laY together form one (CH 2 ) m — wherein m represents 2, 3, 4, or 5). );
- R 6Y represents hydrogen or C 1-4 alkyl.
- a 5Y is hydrogen, CF 3 , -Z 1Y -Z 2Y -Y 2Y (wherein ⁇ 1 ⁇ and ⁇ 2 ⁇ each independently represent a direct bond or a single amino acid residue, ⁇ 2 ⁇ is NH 2 , A C 1-4 alkylamino, di (C 1-4 alkyl) amino or a heterocyclic group bonded to ⁇ 2 ⁇ by a nitrogen atom.), -CH 2 -X 1Y -Y 3Y (in the formula, 1Y represents 0 or S, ⁇ 3 ⁇ represents hetero Ariru to groups represented by) one CH 2 -. Wath display the group represented by Y 3Y. (However, the symbols in the above formulas and groups are extracted from necessary parts.) It is disclosed that the compound has the activity of inhibiting IL-11 release (see PCT International Application No. WO 9309135). ).
- R z represents hydrogen, amino or hydroxy protecting group or benzyloxy optionally substituted on the ring;
- R 7Z represents an C0 2 H, one C0NH0H or biological Aisosuta group.
- a 3Z is one CH 2 — X 1Z — CO— Y 1Z , one CH 2 — 0— Y 2Z or one CH 2 — S— Y 3Z (where ⁇ 1 ⁇ represents 0 or S, and ⁇ 1 ⁇ is alicyclic
- a 1Z and A 2Z are connected together O
- R 1 aZ and R 5Z represent ⁇ to represent C 2-5 alkylene or C 2 -5 alkenylene, and ⁇ 52 represents ——an amino acid optionally protected side chain group or the like. Represents a group represented by. ]
- R 2W represents hydrogen or deuterium
- R 3W represents OH, OR 6W , NR 6W OR 7W or NR 6W R 7W ;
- R 6W and R 7W independently represent hydrogen, alkyl, aralkyl, heteroaralkyl, aryl or heteroaryl;
- R 4W represents hydrogen or alkyl
- R 5W represents hydrogen, alkyl, alkenyl, aryl, heteroaryl, aralkyl, heteroaralkyl, halogen, haloalkyl, nitro, cyano, etc.
- HET W stands for heteroaryl.
- R 11W represents (CR 6W R 7W) 0 _ 6 -R 12W (R 12W represents Ariru, optionally a group selected from among Heteroariru or the R 5W.). ) Represents an amino acid represented by
- the present inventors have conducted intensive studies to find a novel compound having an inhibitory effect on IL-11 converting enzyme, and as a result, have found that the tetrazol derivative represented by the general formula (I) achieves the object. .
- the tetrazole derivative of the present invention is a novel compound that has never been known before.
- R 6 X in the Y x group can represent aryl C 1-6 alkyl.
- tetrazole is not included in the definition of the aryl group, and only a compound represented by the formula (X-1) is disclosed as an example.
- a tetrazole group is essential in the Y portion, and in this point, the compound of the present invention is different from the compound represented by the general formula (X).
- Y 3 Y in the A 5 Y group can represent heteroaryl.
- tetrazole is disclosed as a specific example of heteroaryl.
- specific notes in the specification The publication does not disclose any substituent of the heteroaryl group, and only discloses the compounds represented by the formulas (Y-1) and (Y-2) as examples.
- a substituent other than an alkyl group is essential as a substituent on the tetrazole group in the Y portion.
- the compound of the present invention and the compound represented by the general formula (Y) are different from each other. Is different.
- Y 2Z and ⁇ 3 ⁇ in the A 3Z group can represent a heteroaryl.
- tetrazole is disclosed as a specific example of heteroaryl.
- C 1-4 alkyl substituents are disclosed in the specification as specific examples of the substituent of the heteroaryl group.
- a substituent other than an alkyl group is indispensable as a substituent on the tetrazole group in the ⁇ portion, and in this respect, the compound of the present invention is different from the compound represented by the general formula ( ⁇ ). .
- the ⁇ 3 ⁇ group representing heteroaryl is always bonded to a hetero atom (here, an oxygen atom or a sulfur atom).
- the tetrazole group in the Y portion is always bound to a carbon atom.
- the general formula (I) of the compound of the present invention is different from the general formula (Z). Examples include compounds represented by the general formula (Z-1).
- the compound represented by the general formula (W) may represent HE T w Gaete Roariru in Y w group. Further, the specific description in the specification discloses tetrazole as a heteroaryl. However, no compound representing tetrazole is described in the examples.
- the HET w group representing heteroaryl is always bonded to a heteroatom atom (here, an oxygen atom).
- the tetrazole group in the Y portion is always bound to a carbon atom.
- the compound of the present invention is different from the compound represented by the general formula (W). As an example, there is a compound represented by the general formula (W-1).
- the compound of the present invention is represented by the general formulas (X), (Y), (z), This is a novel compound whose chemical structure is remarkably different from that of the prior art compound represented by, and which has not been known at all.
- the present invention is a.
- J is a single bond, C1-6 alkylene group, C1-6 oxyalkylene group, C1-6 aminoalkylene group, C1-6 thioalkylene group, C2-6 alkenylene group, carbon
- Cy c 1 group (wherein, C yc 1 represents a heterocycle or carbocycle, the rings 1 to 5 hydrogen atoms, C L ⁇ 8 alkyl group, Fuweniru group, phenylene Ruokishi group, A C 1-8 alkyl group substituted by a phenyl group, a halogen atom, a nitro group, a trifluoromethyl group, a nitrile group, a keto group, one OR 2 , —NR 2 R 3 , one CH 2 NR 2 R 3 , One SR 2 , one S (0) R 2 , —S0 2 R 2 , one COO R 2 or one COR 2.
- R 2 may be a hydrogen atom, a Cl-8 alkyl group, a phenyl group, A C 1-4 alkyl group substituted by a phenyl group;
- R 3 represents a hydrogen atom, a C 1-8 alkyl group, a phenyl group, a C 1-4 alkyl group substituted by a phenyl group, a C 2-5 acyl group;
- R 2 and R 3 together with the bonding nitrogen atom represent a heterocyclic ring.
- C yc 1 group Cy c 1 - 0- group, C yc 1 one S- group or C yc 1 - C 0- mono- or di-substituted C 1 to 8 alkyl group by group, C 1 to 8 ⁇ Alkoxy group, C1-8 alkylamino group, di (C1-8 alkyl) amino group or C1-8 alkylthio group,
- C yc 2 group (wherein, Cy c 2 represents a heterocycle or carbocycle, which these rings one to five hydrogen atoms, C L ⁇ 8 alkyl group, Fuweniru group, Hue sulfonyl group Substituted with C 1-4 alkyl, halogen, nitro, trifluoromethyl, nitrile, tetrazole, one OR 5 , one NR 5 R 6 , — SR 5 , one COOR 5 or one COR May be substituted by 5.
- R 5 and R 6 each independently represent a hydrogen atom, a C 1-4 alkyl group, a phenyl group or a C 1-4 alkyl group substituted by a phenyl group.) Or (4) from -OR 7 , one NR 7 R 8 , one SR 7 , -COOR 7 , -COR 7 , one CO NH 2 , one NR 7 —CO—NR 7 R 8 , a guanidino group and Cyc 2 Chosen (Wherein R 7 and R 8 are each independently a hydrogen atom, a C 1-4 alkyl group, a phenyl group or a C 1-4 substituted with a phenyl group) Represents an alkyl group. ),
- R 9 and R 10 are each independently
- Cy c 3 represents a heterocycle or carbocycle, which these rings one to five hydrogen atoms, C L ⁇ 8 alkyl group, Hue group, phenyl C 1-4 alkyl group substituted with a group, halogen atom, nitro group, trifluoromethyl group, nitrile group, tetrazole group, one OR 1
- R 11 and R 12 each independently represent a hydrogen atom, a C 1-4 alkyl group, a phenyl group or a C 1-4 alkyl group substituted by a phenyl group.
- R 13 represents a hydrogen atom, a C 1-4 alkyl group, a phenyl group or a C 1-4 alkyl group substituted by a phenyl group
- R 14 represents a hydrogen atom.
- Atom, C1-4 alkyl group, phenyl group, C1-4 alkyl group substituted by phenyl group, t-butyloxycal Represents a bonyl group or a benzyloxycarbonyl group.
- R 9 and R 10 together represent a C 1-6 alkylene group or a C 2-6 alkenylene group.
- R 15 and R 16 are each independently a hydrogen atom, a C 1-4 alkyl group, a phenyl group, a C 1-4 alkyl group substituted by a phenyl group (however, a C 1-4 alkyl group in the group And the phenyl group may be substituted by a C 1-4 alkyl group, a C 1-4 alkoxy group, a halogen atom, a trifluoromethyl group or a phenyl group.
- Q - 1 carbon atom is an oxygen atom of a medium, a sulfur atom, One SO- group, one S 0 2 - group or a NR 18 - group
- R 18 represents a hydrogen atom, a C 1-4 alkyl group, a C 1-4 alkyl group substituted by a phenyl group or a phenyl group.
- a neighboring hydrogen atom is eliminated. To form a double bond.
- R 19 represents a hydrogen atom, a C1-8 alkyl group, a phenyl group, a C1-4 alkyl group substituted by a phenyl group,
- n an integer of 1 to 4,
- R 26 represents a hydrogen atom, a C 1-4 alkyl group, a phenyl group or a C 1-4 alkyl group substituted by a phenyl group.
- C 1 ⁇ 6 1 carbon atom is an oxygen atom in the alkylene group, a sulfur atom,
- One CO- group, -SO- group, - S0 2 - group, - NR 26 - group R 26 is the same as the Represents a C 1-6 alkylene group replaced by (where Z is bonded to a carbon atom of a tetrazole ring).
- E is a hydrogen atom, a halogen atom, a C 1-4 alkyl group, a COOR 27 group (wherein R 27 is a hydrogen atom, a C 1-4 alkyl group, a phenyl group or a C 1-4 alkyl group substituted by a phenyl group) ), — CONR 28 R 29 group (wherein R 28 and R 29 are each independently a hydrogen atom, a C 1-4 alkyl group, a phenyl group, or a C 1-4 alkyl group substituted by a phenyl group) Or R 28 and R 29 together with the nitrogen atom to be bonded represent a heterocyclic ring.) Or one NR 28 R 29 group (wherein R 28 and R 29 have the same meanings as described above) or
- Cy c 4 group (wherein, C yc 4 represents a heterocyclic ring or carbon ring it these rings one to five hydrogen atoms, C L ⁇ 8 alkyl group, Fuweniru group, the phenyl group substituted C 1 to 4 alkyl groups, halogen atom, nitro group, triflate Ruo Russia methyl, nitrile group, a tetrazo Ichiru group, one OR 24,
- R 24 and R 25 each independently represent a hydrogen atom, a C 1-4 alkyl group, a phenyl group or a C 1-4 alkyl group substituted by a phenyl group.
- R 22 represents a hydrogen atom, a C 1-4 alkyl group, a phenyl group or a C 1-4 alkyl group substituted with a phenyl group
- R 23 represents a hydrogen atom, a C 1-4 alkyl group, a phenyl group, or a phenyl group.
- p represents an integer of 1 to 5.
- Z— E represents a C 1-4 alkyl group or a tri (C 1-4 alkyl) silyl group di-substituted by a halogen atom, trifluoromethyl group or phenyl group.
- the E group shall not represent a hydrogen atom or a C 1-4 alkyl group
- alkyl, alkoxy and alkylene groups include straight-chain and branched ones. Also included are isomers formed by the presence of asymmetric carbon atoms, such as when branched alkyl, alkoxy and alkylene groups are present.
- a C 1-8 alkylamino group represented by R 1 , a Cyc 1 group, a Cyc 1 —0— group, a Cyc 1 —S— group or a Cyc ⁇ CO- group C1-8 alkylamino group in mono- or disubstituted C1-8 alkylamino group is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl substituted by one amino group And isomers thereof.
- a di (C1-8 alkyl) amino group in a di (C1-8alkyl) amino group mono- or disubstituted by a group is methyl, ethyl, propyl, butyl, pentyl, hexyl, to The butyl and octyl groups and their isomers are each independently di-substituted.
- C yc 1 group Cy ci- 0- group, C yc 1 - and S- group or C C 1 to 8 ⁇ alkylthio group yci-CO- in C 1 to 8 alkylthio group which is mono- or di-substituted by group , Methylthio, ethylthio, propylthio, butylthio, pentylthio, hexylthio, heptylthio, octylthio and isomers thereof.
- the C 1-8 alkoxy group in the di-substituted C 1-8 alkoxy group includes methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy and the like.
- the C 1-8 alkoxy group substituted by the C 1-8 alkoxy group represented by R 1 means methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hexoxy, octyloxy.
- a substituent of a carbocyclic or heterocyclic ring in the J group a substituent of R 15 and R 16 , R 5 , R 6 , R 7 , R 8 , shaku 11 , R 12 R 13 ,
- a C 1-4 alkyl group represented by R 14 , R 15 , R 16 , R 18 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , R 28 , R 29 and the E group is Methyl, ethyl, propyl and butyl groups and isomers thereof.
- the C 1-4 alkoxy group represented by the substituents of R 15 and R 16 includes methoxy, ethoxy, propoxy, butoxy and isomers thereof.
- R 16 , R 18 , R 19 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , R 28 and R 29 are a phenyl-substituted C 1-4 alkyl group.
- the C. 1 to 8 alkyl group which phenyl is substituted represented by the substituents of Cy c 1, methylation, which is substituted by one phenyl group, Echiru, propyl, butyl, pentyl, Hexyl, heptyl, octyl groups and isomers thereof.
- the halogen atoms represented by the group and one Z—E group are a fluorine atom, a chlorine atom, a bromine atom and an iodine atom.
- the C 1-6 alkylene group represented by the J group and the Z group and the C 1-6 alkylene group represented by the combination of R 9 and R 10 are methylene, ethylene, trimethylene , Tetramethylene, pentamethylene, hexamethylene, and isomers thereof.
- the C 1-6 oxyalkylene group represented by the J group refers to oxymethylene, oxyethylene, oxytrimethylene, oxytetramethylene, oxypentamethylene, oxyhexamethylene and the isomers thereof. Body.
- the C 1-6 aminoalkylene group represented by the J group refers to aminomethylene, aminoethylene, aminotrimethylene, aminotetramethylene, aminopentamethylene, aminohexamethylene, and isomers thereof. Body.
- the C 1-6 thioalkylene group represented by the J group includes thiomethylene, thioethylene, thiotrimethylene, thiotetramethylene, thiopentamethylene, thiohexamethylene and isomers thereof.
- the C 2 to 6 alkenyl alkylene group C2 ⁇ 6 alkenyl alkylene group and R 9 and R 10 is represented by J and Z groups are combined to a connexion represented, vinylene, propenylene, Butenylene, pentenylene, hexenylene, butagenylene, pentagenenylene, hexenenylene, hexatrienylene group and isomers thereof.
- the C 2-8 alkenyl group represented by R 1 means vinyl, bronilyl, butenyl, pentenyl, hexenyl, hebutenyl, octenyl, butadienyl, pentajenyl, hexagenyl, heptaje Nyl, octagenyl, hexatrienyl, heptatrienyl, octatrienyl group and isomers thereof.
- the C 2-8 alkenyloxy group represented by R 1 is vinyloxy, bronoxy, butenyloxy, pentenyloxy, hexenyloxy, hebutenyloxy, succinyloxy, butadienyloxy, pentagenioxy. Roxy, hexogenyloxy, heptagenyloxy, octagenyloxy, hexatrienyloxy, heptatrienyloxy, octatrienyloxy and isomers thereof.
- the tri (C1-4 alkyl) silyl group represented by one Z—E group means a methyl, ethyl, propyl, butyl group or a different isomer of the silyl atom. And tri-substituted.
- the carbocycle represented by represents a C3-10 monocyclic and bicyclic carbocycle.
- C 3-10 monocyclic and bicyclic carbocycles include cyclobut Mouth pill, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentadiene, benzene, pentalene, indene, naphthalene, azulene and the like.
- 5- to 18-membered monocyclic, bicyclic or tricyclic heterocycles containing 1-2 nitrogen atoms, one oxygen atom or sulfur atom include pyrrol, imidazole, triazole, Pyrazols, pyridines, pyrazines, pyrimidines, pyridazines, azepines, diazepines, furans, pyrans, oxepins, oxazepines, thiophenes, thianes (thiopyrans), chepins, oxazols, isoxazoles, thiazoles, oxizazoles, oxazines , Oxaziazine, oxazezepine, oxazineazepine, thiaziazole,
- heterocyclic ring R 2 and R 3 heterocyclic or R 2 8 and R 2 9 are Iconnection table as together with the nitrogen atom bonded is represented by summer together with the nitrogen atom bonded Represents a nitrogen-containing 5- to 7-membered monocyclic heterocyclic ring containing 1 to 2 nitrogen atoms, 1 oxygen atom or sulfur atom.
- nitrogen-containing 5- to 7-membered monocyclic heterocycles containing 1 to 2 nitrogen atoms, 1 oxygen atom or sulfur atom include, for example, pyrrolidine, pyrrolidine, imidazoline, imidazolidine, pyrazoline, virazolidinine, Piperidine, piperazine, piperidine, piperazine, morpholine, thiomorpholine, tetrahydropyrimidine, tetrahydropyridazine ring and the like.
- glycine, alanine, serine, threonine, cysteine, phos methionine, leucine, isofacin, feniralanine, tyrosine, tributofan, aspartic acid
- examples include glutamic acid, arginine, glutamine, lysine, and histidine residues.
- glycine, alanine, serine, threonine, cystine, / phosphorus, methionine, leucine examples include isine, phenylalanine, tyrosine, tributofan, aspartic acid, glutamic acid, arginine, glutamine, lysine, histidine, and proline residues.
- the C 1-4 alkyl group in which the phenyl group represented by one Z—E group is di-substituted refers to methyl, ethyl, propyl, butyl and the like substituted by two phenyl groups. Is an isomer of
- keto group as a substituent of C yc 1 groups one on the same carbon atom, one nitrogen atom, can be one or two substituted with a sulfur atom.
- the non-toxic salt in the present invention includes all salts. For example, the following salts, acid addition salts, hydrates and the like can be mentioned.
- salts of alkali metals include salts of alkali metals (potassium, sodium, etc.), salts of alkaline earth metals (calcium, magnesium, etc.), ammonium salts, pharmaceutically acceptable organic amines (tetramethylammonium, etc.).
- the compound of the present invention represented by the general formula (I) is converted into a corresponding acid addition salt by a known method.
- the acid addition salts are preferably non-toxic and water-soluble. Suitable acid addition salts include hydrochloride, hydrobromide, sulfate, phosphate, nitrate Inorganic acid salts such as, or acetate, trifluoroacetate, lactate, tartrate, oxalate, fumarate, maleate, citrate, benzoate, methanesulfonate, ethanesulfonate And organic salts such as benzenesulfonate, toluenesulfonate, isethionate, glucuronate, and gluconate.
- the compound of the present invention represented by the general formula (I) or a salt thereof can also be converted into a hydrate by a known method.
- R 1 has the same meaning as described above.
- Their non-toxic salts, their acid addition salts, and their hydrates Preferred specific examples of the compound represented by the general formula (I) include the compounds described in Tables 1 to 77 below, their non-toxic salts, their acid addition salts, their hydrates, and those described in the Examples. And the like.
- R A , AA 1A , AA 2A and Y A have the same meanings as R, AA ⁇ AA 2 and Y, provided that R A , AA 1A , AA 2A and Y A each represent one COOH group
- the compound of the present invention represented by the formula (1) can be produced by the following methods (a) and (b).
- R A does not represent an amino group-containing group
- AA 1A does not represent an amino group-containing group
- AA 2A represents an amino group.
- R A — a , AA 1A — a , AA 2A — a and Y A — a have the same meaning as R A , AA 1A , AA 2A and Y A , provided that R A- 1a , AA 1A, none of the AA 2A one a and Y a one a shall not represent a group containing an amino group, and Y a - also one Z- E group in a group is bound to the carbon atom of the tetrazole
- the compound of the present invention represented by can be produced by the following method (a-1), (a-2), (a-3) or (a-4).
- R 19A represents a C 1-8 alkyl group, a phenyl group, or a C 1-4 alkyl group substituted by a phenyl group
- X A — a — 1 is a leaving group (for example, a chlorine atom, Represents a bromine atom, an iodine atom, a mesyl group, a tosyl group, etc.), and the other symbols have the same meanings as described above.)
- This reaction is known, for example, by performing the reaction at a temperature of 20 to 40 in an organic solvent (for example, N, N-dimethylformamide or the like) in the presence of potassium fluoride or the like.
- an organic solvent for example, N, N-dimethylformamide or the like
- Upsilon Alpha one a one 2 have the same meanings as Upsilon Alpha one a proviso, Y A -.
- the Z—E group represents a tri (C 1-4 alkyl) silyl group, and the other symbols have the same meanings as described above.
- the compound of the present invention represented by the general formula (II-a-2)
- R "-a-2-1, RII-a-2-2 and R '"-a-2-2-3 are each independently
- a compound that forms an amide bond, a sulfonamide bond, or a sulfonylprea bond by bonding to the NH group to which 1 ⁇ 8 group and 88, AA 2A - a or YA- a are bonded that is, a general formula (I— A_a— 3) ⁇ - ⁇ ⁇ 3- A ⁇ 1A-a- 3_ AjA 2A-a-3_DO ⁇ ⁇ 8 ( ⁇ - ⁇ - ⁇ -3)
- R A -a— 3 , AA 1A — a — 3 and AA 2A — a — 3 represent the same meaning as R A — a , AA 1A — a and AA 2A - a , where R A one 3 - 3 groups and AA IA - a - 3, AA 2A - a- 3 or bond to the amino linkage thereof with NH groups bonded to the Y A one a, scan Ruhon'ami de attached, as forming Suruhoniruurea bond, the other symbols as defined above Express.
- the compound of the present invention represented by the general formula (II-a-3)
- X A —a — 3 represents a leaving group (for example, a chlorine atom, a bromine atom, an iodine atom, etc.) or a hydroxyl group, and the other symbols have the same meanings as described above.)
- X A —a — 3 represents a leaving group (for example, a chlorine atom, a bromine atom, an iodine atom, etc.) or a hydroxyl group, and the other symbols have the same meanings as described above.)
- III-a-3 represents a leaving group (for example, a chlorine atom, a bromine atom, an iodine atom, etc.) or a hydroxyl group, and the other symbols have the same meanings as described above.)
- This reaction is carried out by amidation, sulfonamidation, sulfonylation, or a similar method.
- the method using an acid halide is, for example, a method in which a carboxylic acid is dissolved in an inert organic solvent (eg, chloroform, methylene chloride, dimethyl ether, tetrahydrofuran) or without a solvent.
- an inert organic solvent eg, chloroform, methylene chloride, dimethyl ether, tetrahydrofuran
- Acid halides oxalil chloride, thiyl chloride, etc.
- the reaction is carried out at C to reflux temperature, and the resulting acid halide is converted to a tertiary amine (pyridine, triethyla).
- a method using a mixed acid anhydride is described, for example, by adding a carboxylic acid to a tertiary amine (pyridine) in an inert organic solvent (e.g. , Triethylamine, dimethylaniline, dimethylaminopyridine, etc.), acid halides (eg, porcine ilk mouth, tossil mouth, mesylcum ride), or acid derivatives (eg, ethyl ethyl chloroformate, chloroformate).
- a carboxylic acid to a tertiary amine (pyridine) in an inert organic solvent
- an inert organic solvent e.g. , Triethylamine, dimethylaniline, dimethylaminopyridine, etc.
- acid halides eg, porcine ilk mouth, tossil mouth, mesylcum ride
- acid derivatives eg, ethyl ethyl chloroformate, chloroformate
- Condensing agent (1,3-dicyclohexylcarbodiimide (DCC), 1-ethyl-3- [3- (dimethylamino) propyl] carbodiimide (EDC), 2-chloro-1-methylpyridinium
- DCC dicyclohexylcarbodiimide
- EDC 1-ethyl-3- [3- (dimethylamino) propyl] carbodiimide
- 2-chloro-1-methylpyridinium a method using iodinated tertiary amine (pyridine) in an inert organic solvent (e.g., chloroform, methylene chloride, dimethylformamide, and getyl ether) or without solvent is used.
- Triethylamine, dimethylaniline, dimethylaminoviridine, etc. with or without a condensing agent at 0 to 40 ° C.
- Sulfonamidation is well known.
- sulfonic acid can be converted to an acid halide (oxalyl chloride) in an inert organic solvent (eg, chloroform, methylene chloride, dimethyl ether, tetrahydrofuran) or in the absence of a solvent.
- an inert organic solvent eg, chloroform, methylene chloride, dimethyl ether, tetrahydrofuran
- a tertiary amine pyridine, triethylamine, dimethylaniline, dimethylaminopyridine, etc.
- the reaction is carried out by reacting the amine with an amine in an inert organic solvent (e.g., chloroform, methylene chloride, getyl ether, tetrahydrofuran, etc.) in the presence of water.
- an inert organic solvent e.g., chloroform, methylene chloride, getyl ether, tetrahydrofuran, etc.
- an aminosulfonic acid derivative can be prepared by using an acid halide (oxalyl chloride) in an inert organic solvent (eg, chloroform, methylene chloride, dimethyl ether, tetrahydrofuran) or in the absence of a solvent.
- an acid halide oxalyl chloride
- an inert organic solvent eg, chloroform, methylene chloride, dimethyl ether, tetrahydrofuran
- Thionyl chloride, phosphorus pentachloride, phosphorus trichloride, etc. at a temperature of from 20 ° C to reflux temperature
- the resulting aminosulfonyl halide derivative is reacted with a tertiary amine (pyridine, triethylamine, dimethylaniline, dimethylaminopyridine, etc.).
- a tertiary amine pyridine, triethylamine, dimethylaniline, dimethylaminopyridine
- R 1A - a -4, J A - a - 4 , AA 1A 4 and AA 2A - a - 4 represent the same meaning as RJ, AA 1A - a and AA 2A - a , where R- a one JA-
- the a- 4 group shall not represent a group containing one COO H group or a group containing an amino group
- R 1A — a — 4 — J A — a — four groups may form a carbonyl group via an NH group.
- the other symbols have the same meanings as described above.
- the ureation reaction is known, and for example, amides (for example, triethylamine, pyridine, and pyridine) in an inert organic solvent (for example, dimethylformamide, dichloromethane, tetrahydrofuran and the like) using N, N, —carbodiimidazole are used.
- amides for example, triethylamine, pyridine, and pyridine
- an inert organic solvent for example, dimethylformamide, dichloromethane, tetrahydrofuran and the like
- N, N, —carbodiimidazole are used.
- the reaction is carried out at 0 to 80 ° C in the presence or absence of methylpyridine.
- R A — b , AA 1A to AA 2A — b and Y A — b represent the same meaning as R A , AA 1A , AA 2A and Y A.
- R A- 1b , AA 1A The compound of the present invention represented by the following formula (b-1) or (B-1), wherein at least one group out of ⁇ AA 2A — b and Y A- b represents a group containing an amino group. It can be manufactured by the method of b-2).
- the compound of the present invention represented by the general formula (I-A-b) can be prepared in the same manner as in the above-mentioned (a-1), (a-2), (a-3) and (a-4). And a protecting group having a generally known amino group such as t-butyloxycarbonyl group, benzyloxycarbonyl group, triphenylmethyl group, 2- (trimethylsilyl) ethoxymethyl group or trifluoromethyl group. compounds protected by Roasechiru group), namely the general formula (II- b- 1) oA-llb -1__ * A 1 A-llb-1_ A ⁇ 2A-I «b-1_ _ yA-llb-1 ( ll-b-1)
- RA- ", AA 1 a - ! H b- 1, AA 2A - IIB - 1 and Y A - H b-1 is, R A - b, AA 1A - b, AA 2A _ b and Y Represents the same meaning as A - b , except that at least one of RA- I Ib —], AA 1A- 1 I Ib —], AA 2A — I Ib — 1 and Y A- 1 1 b — 1 is general Protected by a commonly known amino protecting group (for example, t-butyloxycarbonyl group, benzyloxycarbonyl group, triphenylmethyl group, 2- (trimethylsilyl) ethoxymethyl group or trifluoroacetyl group) The compound represented by) is subjected to a deprotection reaction of an amino-protecting group.
- a commonly known amino protecting group for example, t-butyloxycarbonyl group,
- the deprotection reaction of an amino-protecting group differs depending on the protecting group, but is known.
- the protecting group is t-butyloxycarbonyl, Rume
- an aqueous solution of an organic acid eg, acetic acid, trifluoroacetic acid, etc.
- an organic solvent miscible with water eg, methanol, tetrahydrofuran, dioxane, acetone, etc.
- the reaction is carried out at a temperature of 0 to 100 in an aqueous solution of an inorganic or inorganic acid (eg, hydrochloric acid, sulfuric acid, etc.) or a mixture thereof.
- the protecting group is a benzyloxycarbonyl group
- Hydrogenolysis reactions include, for example, inert solvents [ether-based (eg, tetrahydrofuran, dioxane, gemethoxetane, getyl ether, etc.), alcohol-based (eg, methanol, ethanol, etc.), benzene-based (eg, benzene] , Toluene, etc.), ketones (eg, acetone, methyl ethyl ketone, etc.), nitriles (eg, acetonitrile, etc.), amides (eg, dimethylformamide, etc.), water, ethyl acetate, acetic acid Or a mixture of two or more thereof] in the presence of a hydrogenation catalyst (eg, palladium monocarbon, palladium black, palladium, palladium hydroxide, platinum dioxide, nickel, Ra
- the alkali metal hydroxide sodium hydroxide, potassium hydroxide
- a water-miscible organic solvent eg, methanol, tetrahydrofuran, dioxane, acetone, etc.
- alkaline earth metal hydroxide barium hydroxide, calcium hydroxide, etc.
- carbonate potassium carbonate, sodium carbonate, etc.
- the protecting group for the amino group is other than t-butyloxycarbonyl group, benzyloxycarbonyl group, triphenylmethyl group, 2- (trimethylsilyl) ethoxymethyl group and trifluoroacetyl group.
- the protecting group for the amino group is other than t-butyloxycarbonyl group, benzyloxycarbonyl group, triphenylmethyl group, 2- (trimethylsilyl) ethoxymethyl group and trifluoroacetyl group.
- those described in “Protective Groups in Organic Synthesis J (TW Greene, Wiley, New York (1991))” can be used.
- the desired compound of the present invention can be easily produced. can do.
- the reduction reaction of the nitro group is known and is carried out, for example, by a hydrogenolysis reaction or a reduction reaction using an organic metal.
- the hydrogenolysis reaction is performed by the method described above.
- Reduction reactions using organometallics are known, for example, water-miscible solvents (e.
- the reaction is carried out at a temperature of 50 to 150 ° C using an organic metal (zinc, iron, tin, tin chloride, iron chloride) in an aqueous solution of hydrochloric acid in the presence or absence of aqueous hydrochloric acid.
- At least one of R, AA 1 , AA 2 and Y represents a group containing one CO OH group, that is, a compound represented by the general formula (I-B)
- R B , AA 1B , AA 2B and Y B represent the same meaning as R, AA AA 2 and Y, provided that at least one of R B , AA 1B , AA 2B and Y B is The compound of the present invention represented by the general formula (I-1A) produced by the above-mentioned method, wherein one C00H group in the target compound of the general formula (I-A) is a t-butyl ester group.
- R A — AA 1A — AA 2A — 1 and Y A — 1 represent the same meaning as R A , AA 1A , AA 2A and Y A , provided that R A- 1 , AA 1A- ⁇ AA
- At least one of 2A - 1 and YA- 1 represents a group containing a t-butyl ester group, a benzyl ester group, an alkyl ester group, or a 2,2,2-trichloroethyl ester group.
- the t-butyl esthetic A hydrolysis reaction, a hydrogenolysis reaction, an ester hydrolysis reaction, or a cleavage reaction of a 2,2,2-trichloroethyl ester group.
- Hydrolysis of the t-butyl ester group is known, for example, in an inert organic solvent (eg, methylene chloride, chloroform, methanol, dioxane, ethyl acetate, anisol, etc.), an organic acid (eg, trifluorosulfuric acid, etc.)
- an inert organic solvent eg, methylene chloride, chloroform, methanol, dioxane, ethyl acetate, anisol, etc.
- an organic acid eg, trifluorosulfuric acid, etc.
- the reaction is performed at a temperature of 0 to 90 ° C. in an inorganic acid (for example, hydrochloric acid or the like) or a mixture thereof.
- the hydrogenolysis reaction is performed by the method described above.
- Ester hydrolysis reactions are known and are carried out, for example, under acid or alkaline conditions.
- Hydrolysis under alkaline conditions is carried out in a suitable solvent (eg, methanol, dimethoxetane, etc.) using an alkali metal hydroxide, an alkaline earth metal hydroxide or carbonate in an amount of 0 to 40%.
- a suitable solvent eg, methanol, dimethoxetane, etc.
- the hydrolysis under acid conditions is performed in the same manner as the hydrolysis of the t-butyl ester group.
- Cleavage reactions of 2,2,2-trichloroethyl ester groups are known.
- acidic solvents acetic acid, a buffer solution of ⁇ 4.2 to 7.2 or a mixture thereof with an organic solvent such as tetrahydrofuran
- Liquid in the presence of powdered zinc, with or without sonication, at a temperature between 0 and 40.
- the protecting group for the carboxy group may be other than t-butyl ester group, benzyl ester group and 2,2,2-trichloroethyl ester group.
- the group is not particularly limited as long as it is a group which can be eliminated easily and selectively.
- those described in “Protective Groups in Organic Synthesis” TW Greene, Wiley, New York (1991)
- the compound of the present invention can be easily produced.
- R c , AA 1C , AA 2C and Y c represent the same meaning as R, AA ⁇ AA 2 and Y, provided that all of R c , AA 1C , AA 2C and Y c are — COOH groups
- the compound of the present invention which does not represent an amino group-containing group and the Z group or R 2 Q in Y c represents an amide group, is represented by the aforementioned general formula (IB)
- amidation reaction between the C00H group and the amine compound is carried out by the method described above.
- the amidation reaction between the methyl ester or ethyl ester and the amine compound is carried out in a water-miscible solvent (eg, methanol, ethanol) by the general formula (III-I).
- a water-miscible solvent eg, methanol, ethanol
- the reaction is performed at room temperature with the amine aqueous solution represented by C-1).
- any one of R, AA 1 , AA 2 and Y represents a group containing one COOH group or an amino group, and the Z group in Y
- the compound in which R 2 Q represents an amide group can also be obtained by subjecting the compound prepared by the general formula (I-C) to the above-mentioned deprotection reaction of an amino group and carboxyl group. Can be manufactured.
- the compound represented by the general formula (II-a-1) can be produced by a known method, for example, a method described in Med. Chem., 37, 563 (1994), European Patent Application Publication No. 0623592 or the like. Can be.
- the reaction product is purified by a conventional purification means, for example, distillation under normal pressure or reduced pressure, high performance liquid chromatography using silica gel or magnesium silicate, thin layer chromatography, or column. It can be purified by a method such as chromatography or washing and recrystallization. Purification may be performed for each reaction or after completion of several reactions.
- a conventional purification means for example, distillation under normal pressure or reduced pressure, high performance liquid chromatography using silica gel or magnesium silicate, thin layer chromatography, or column. It can be purified by a method such as chromatography or washing and recrystallization. Purification may be performed for each reaction or after completion of several reactions.
- IL-1 converting enzyme reaction solution (containing 2 OmM HEPES 'sodium hydroxide buffer pH 7.4, 1 OmM potassium chloride, 1.5 mM magnesium chloride, 0.1 mM EDTA and 10% glycerol) was prepared.
- preferred compounds of the present invention have the following IC 5 . (E.g., the compound of Example 2 (1) the IC 50 was 0.03 off.) Was shown to be inhibited by.
- HE PES is 4- (2-hydroxyhydricyl) -1-piperazineethanesulfonate
- EDT A is ethylenediaminetetraacetic acid
- Ac-Tyr-Val-Ala-Asp-MCA is acetyl-L-tyrosyl-L-valinyl-
- the toxicity of the compound of the present invention is very low, and it can be judged that the compound is sufficiently safe for use as a medicine.
- the compound of the present invention has an inhibitory effect on interleukin-11-converting enzyme in animals including humans, particularly in humans.
- Disease infectious disease, complications of infection, septic shock, arthritis, colitis, glomerulonephritis, hepatitis, cirrhosis, armitis, reperfusion injury, cholangitis, encephalitis, endocarditis, myocarditis, pericarditis, Hepatitis hepatitis, Alhaima disease, Parkinson's disease, dementia, cerebrovascular disease, neurodegenerative disease, bone and cartilage resorption disease, osteoarthritis, Crohn's disease, AIDS, ARC (AIDS-related disease), adult T Cell leukemia, hairy cell leukemia, myelopathy, respiratory tract disorders, arthropathy, uveitis, cancer, collagen diseases such as systemic lupus erythematosus and rheumatoid arthritis, ulcerative colitis, Sjogren's syndrome
- the compound of the present invention represented by the general formula (I), a non-toxic acid addition salt thereof, or a hydrate thereof for the above-mentioned purpose is usually administered systemically or locally in an oral or parenteral form. Is administered.
- Dosage varies depending on age, body weight, symptoms, therapeutic effect, administration method, treatment time, etc., but is usually in the range of lmg to 1000mg per adult, once to several times a day. Oral or per adult, 1 Parenteral administration (preferably intravenous) once or several times daily in the range of 1 mg to 100 mg per dose, or intravenous in the range of 1 hour to 24 hours daily Is administered continuously.
- the dose varies depending on various conditions, so that a dose smaller than the above dose may be sufficient, or may be required beyond the range.
- the compound of the present invention When the compound of the present invention is administered, it is used as a solid composition, a liquid composition and other compositions for oral administration and an injection, an external preparation, a suppository and the like for parenteral administration.
- Solid compositions for oral administration include tablets, pills, capsules, powders, granules and the like.
- Capsules include hard capsules and soft capsules.
- one or more active substance powers, at least one inert diluent, such as lactose, mannitol, glucose, hydroxybutyryl cellulose, microcrystalline cellulose, starch, polyvinylpyrrolid Don, mixed with magnesium aluminate metasilicate.
- the composition may be formulated according to conventional methods, with additives other than inert diluents, for example, lubricants such as magnesium stearate, disintegrants such as calcium cellulose glycolate, stabilizers such as lactose, glutamic acid.
- a solubilizing agent such as aspartic acid may be contained.
- Tablets or pills may be coated with a film of gastric or enteric substance such as sucrose, gelatin, hydroxypropyl cellulose, hydroxypropylmethylcellulose phthalate, etc., if necessary. May be coated. Also included are capsules of absorbable materials such as gelatin.
- Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions and syrups. Tablets and elixirs. In such liquid compositions, one or more active substances are contained in a commonly used inert diluent (eg, purified water, ethanol). The composition may contain, in addition to the inert diluent, adjuvants such as wetting agents and suspending agents, sweetening agents, flavoring agents, fragrances, and preservatives.
- adjuvants such as wetting agents and suspending agents, sweetening agents, flavoring agents, fragrances, and preservatives.
- compositions for oral administration include sprays which contain one or more active substances and are formulated in a manner known per se.
- the composition may contain, in addition to the inert diluent, a buffering agent that provides isotonicity with stabilizers such as sodium bisulfite, for example, isotonic agents such as sodium chloride, sodium citrate, or citrate. You can do it.
- a buffering agent that provides isotonicity with stabilizers such as sodium bisulfite, for example, isotonic agents such as sodium chloride, sodium citrate, or citrate. You can do it.
- the process for the preparation of the soubrant agent is described in detail, for example, in U.S. Pat. Nos. 2,868,691 and 3,095,355.
- Injections for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
- Aqueous solutions and suspensions include, for example, distilled water for injection and physiological saline.
- water-insoluble solutions and suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohols such as ethanol, and Polysorbate 80 (registered trademark).
- Such compositions may also contain adjuvants such as preserving, wetting, emulsifying, dispersing, stabilizing (eg, lactose), and solubilizing agents (eg, glutamic acid, aspartic acid). Good.
- bactericides are sterilized by filtration through a bacteria-retaining filter, blending of a bactericide or irradiation. They can also be used to produce sterile solid compositions, for example, sterilized or dissolved in sterile distilled water for injection or other solvents before use of the lyophilized product.
- compositions for parenteral administration include one or more It contains active substances and includes external solutions, ointments, liniments, suppositories for rectal administration, and pessaries for vaginal administration, which are formulated in a conventional manner.
- BEST MODE FOR CARRYING OUT THE INVENTION will be described in detail with reference examples and examples, but the present invention is not limited thereto.
- N ((N— (3-phenylpropionyl) -1-L-valinyl) -1-L-alanyl) -3-amino-4-oxo-15-bromopentanoic acid 't-butyl ester [ ⁇ Med. Chem., 37 , 563 (1994). ] (298 mg) in a solution of N, N-dimethylformamide (5 ml) was added potassium fusidani (144 mg) and 5- (2,6-dichloromethylphenylmethyl) tetrazole (249 mg). The reaction mixture was stirred at room temperature for 1 day. Water was added to the reaction mixture, which was extracted with ethyl acetate.
- Example 2 The same operation as in Example 1 was carried out using a corresponding tetrazole compound instead of 5- (2,6-dichloromethylphenylmethyl) tetrazole to obtain the following compound of the present invention.
- Trifluoroacetic acid (2 ml) was added to a solution of the compound (1) (23 mg) produced in Example 1 in thioanisole (0.17 ml) and m-cresol (0.15 ml). The reaction mixture was stirred at room temperature for 30 minutes. The reaction mixture was concentrated by adding toluene, and the residue was washed with ether and dried to give the compound of the present invention (17 mg) having the following physical data.
- Example 2 (1) The same operation as in Example 2 (1) was performed using the compounds of Examples 1 (2) to 1 (6) in place of the compound (1) produced in Example 1, and if necessary, the corresponding salt was converted to a compound of the present invention shown below.
- Example 3 (1) to 3 (7) Using the compounds of Examples 3 (1) to 3 (7) in place of the compound (1) produced in Example 1, the same operation as in Example 2 (1) was carried out, and the present invention shown below The compound was obtained.
- Example 1 N-((N- (3-phenylpropionyl) -l-valinyl) -l-alanyl) l-amino-4-oxo-15-bromopentanoic acid N-benzyloxy instead of t-butyl ester Tetrazole compounds corresponding to carbonyl 3-amino-4-oxo-1-5-bromopentanoic acid 't-butyl ester
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/101,004 US6136834A (en) | 1995-12-27 | 1996-12-26 | Tetrazole compounds and pharmaceutical agents containing such derivative |
EP96942651A EP0900791A1 (en) | 1995-12-27 | 1996-12-26 | Tetrazole derivatives and drugs containing the same as the active ingredient |
KR19980704944A KR19990076818A (ja) | 1995-12-27 | 1998-06-26 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP35124195 | 1995-12-27 | ||
JP7/351241 | 1995-12-27 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/572,569 Division US6376484B1 (en) | 1995-12-27 | 2000-05-16 | Tetrazole compounds and pharmaceutical agents containing such derivative as an active ingredient |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997024339A1 true WO1997024339A1 (fr) | 1997-07-10 |
Family
ID=18416011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1996/003801 WO1997024339A1 (fr) | 1995-12-27 | 1996-12-26 | Derives de tetrazole et medicaments les contenant a titre d'ingredients actifs |
Country Status (4)
Country | Link |
---|---|
US (2) | US6136834A (ja) |
EP (1) | EP0900791A1 (ja) |
KR (1) | KR19990076818A (ja) |
WO (1) | WO1997024339A1 (ja) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6197770B1 (en) | 1999-03-03 | 2001-03-06 | The Procter & Gamble Co. | Alkenyl- and alkynl-containing metalloprotease inhibitors |
WO2001068655A2 (en) * | 2000-03-10 | 2001-09-20 | Ariad Pharmaceuticals, Inc. | Caprolactam derivatives and uses thereof |
US6426413B1 (en) | 1998-03-09 | 2002-07-30 | Vertex Pharmaceuticals Incorporated | Inhibitors of caspases |
JP2002527510A (ja) * | 1998-10-16 | 2002-08-27 | アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | インターロイキン−1−βインヒビターとしての置換されたチアジアゾールスルホンアミド |
US6489308B1 (en) | 1999-03-05 | 2002-12-03 | Trustees Of University Of Technology Corporation | Inhibitors of serine protease activity, methods and compositions for treatment of nitric-oxide-induced clinical conditions |
US6531474B1 (en) | 1998-03-19 | 2003-03-11 | Vertex Pharmaceuticals Incorporated | Inhibitors of caspases |
JP2003534325A (ja) * | 2000-05-23 | 2003-11-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | カスパーゼインヒビター及びその使用 |
US6762198B2 (en) | 1999-03-03 | 2004-07-13 | The Procter & Gamble Company | Dihetero-substituted metalloprotease inhibitors |
WO2004080983A1 (en) * | 2003-03-14 | 2004-09-23 | Astrazeneca Ab | Novel lactams and uses thereof |
US6981659B1 (en) | 1999-05-06 | 2006-01-03 | Gordon Duane Hopkins | Liquid mist fire extinguisher |
US7074782B2 (en) | 2000-03-29 | 2006-07-11 | Vertex Pharmaceuticals Incorporated | Carbamate caspase inhibitors and uses thereof |
EP1923386A2 (en) | 2000-03-29 | 2008-05-21 | Vertex Pharmceuticals Incorporated | Carbamate caspase inhibitors and uses thereof |
US7704958B1 (en) | 1999-03-05 | 2010-04-27 | Bio Holding, Inc. | Methods and compositions for inhibiting apoptosis using serine protease inhibitors |
US7858776B2 (en) | 2002-10-03 | 2010-12-28 | Astrazeneca Ab | Lactams and uses thereof |
EP2520654A1 (en) | 2003-08-26 | 2012-11-07 | The Regents of the University of Colorado | Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections |
US8329662B2 (en) | 2000-05-19 | 2012-12-11 | Vertexd Pharmaceuticals Incorporated | Prodrug of an ICE inhibitor |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6849605B1 (en) * | 1999-03-05 | 2005-02-01 | The Trustees Of University Technology Corporation | Inhibitors of serine protease activity, methods and compositions for treatment of viral infections |
AU2001228811A1 (en) | 2000-01-26 | 2001-08-07 | Ono Pharmaceutical Co. Ltd. | Nitrogen-containing 5-membered cyclic compounds and drugs containing these compounds as the active ingredient |
WO2002060894A2 (en) | 2001-01-30 | 2002-08-08 | Bristol-Myers Squibb Company | Sulfonamide lactam inhibitors of factor xa |
WO2003068242A1 (en) * | 2002-02-11 | 2003-08-21 | Vertex Pharmaceuticals Incorporated | Phospholipids as caspase inhibitor prodrugs |
US7001899B2 (en) * | 2002-06-10 | 2006-02-21 | The Procter & Gamble Company | Interleukin converting enzyme inhibitors |
US7863317B2 (en) * | 2003-08-21 | 2011-01-04 | Bristol-Myers Squibb Company | Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity |
US20050043392A1 (en) * | 2003-08-21 | 2005-02-24 | Carter Percy H. | Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity |
US20050124684A1 (en) * | 2003-08-29 | 2005-06-09 | Ying Du | 5-(hydroxymethyl) furfural and derivatives as inhibitors of TNFalpha and IL-1beta production |
CN1980658A (zh) * | 2004-05-27 | 2007-06-13 | 沃泰克斯药物股份有限公司 | 治疗自身炎性疾病的ice抑制剂 |
US9938353B2 (en) | 2011-06-24 | 2018-04-10 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
CA2896951A1 (en) | 2012-01-10 | 2013-07-18 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
WO2017136727A2 (en) | 2016-02-05 | 2017-08-10 | Denali Therapeutics Inc. | Compounds, compositions and methods |
ES2912295T3 (es) | 2016-12-09 | 2022-05-25 | Denali Therapeutics Inc | Compuestos útiles como inhibidores de RIPK1 |
TW202334164A (zh) | 2022-01-12 | 2023-09-01 | 美商戴納立製藥公司 | (S)-5-苄基-N-(5-甲基-4-側氧基-2,3,4,5-四氫吡啶並[3,2-b][1,4]氧氮呯-3-基)-4H-1,2,4-三唑-3-甲醯胺的晶型 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993009135A1 (en) * | 1991-11-04 | 1993-05-13 | Sandoz Ltd. | Peptides inhibiting il-1 beta release |
EP0618223A2 (en) * | 1993-03-08 | 1994-10-05 | Sandoz Ltd. | Peptides inhibiting interleukin 1-bêta release useful as antiinflammatory agents |
EP0644198A1 (en) * | 1993-06-03 | 1995-03-22 | Sterling Winthrop Inc. | Alpha-heteroaryloxymethyl ketones as interleukin-1beta converting enzyme inhibitors |
WO1995026598A2 (en) * | 1994-03-18 | 1995-10-05 | Philips Electronics N.V. | A spread-spectrum based cellular mobile radio system, and a control arrangement, a radio base station, and a mobile radio station |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ228855A (en) * | 1988-04-25 | 1992-08-26 | Hoffmann La Roche | Tyrosine analogues and peptides containing them especially cholecystokinin (cck) analogues |
EP0519748B1 (en) * | 1991-06-21 | 1998-09-02 | Merck & Co. Inc. | Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme |
US5371072A (en) * | 1992-10-16 | 1994-12-06 | Corvas International, Inc. | Asp-Pro-Arg α-keto-amide enzyme inhibitors |
DE4310088A1 (de) | 1993-03-27 | 1994-09-29 | Hoechst Ag | Verfahren zur Herstellung und Aufarbeitung von in wäßrigem Medium löslichen N-Hydroxyalkylchitosanen |
HU224731B1 (en) * | 1994-03-31 | 2006-01-30 | Vertex Pharma | Pyrimidinyl derivatives as interleukin inhibitors and pharmaceutical compositions containing them |
EP0761680A3 (en) * | 1995-09-12 | 1999-05-06 | Ono Pharmaceutical Co., Ltd. | Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity |
US6194435B1 (en) * | 1996-10-11 | 2001-02-27 | Cor Therapeutics, Inc. | Lactams as selective factor Xa inhibitors |
US6239127B1 (en) * | 1999-11-17 | 2001-05-29 | Novartis Ag | Certain substituted caprolactams, pharmaceutical compositions containing them and a process for their preparation |
-
1996
- 1996-12-26 US US09/101,004 patent/US6136834A/en not_active Expired - Fee Related
- 1996-12-26 WO PCT/JP1996/003801 patent/WO1997024339A1/ja active Search and Examination
- 1996-12-26 EP EP96942651A patent/EP0900791A1/en not_active Withdrawn
-
1998
- 1998-06-26 KR KR19980704944A patent/KR19990076818A/ko not_active Application Discontinuation
-
2000
- 2000-05-16 US US09/572,569 patent/US6376484B1/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993009135A1 (en) * | 1991-11-04 | 1993-05-13 | Sandoz Ltd. | Peptides inhibiting il-1 beta release |
EP0618223A2 (en) * | 1993-03-08 | 1994-10-05 | Sandoz Ltd. | Peptides inhibiting interleukin 1-bêta release useful as antiinflammatory agents |
EP0644198A1 (en) * | 1993-06-03 | 1995-03-22 | Sterling Winthrop Inc. | Alpha-heteroaryloxymethyl ketones as interleukin-1beta converting enzyme inhibitors |
WO1995026598A2 (en) * | 1994-03-18 | 1995-10-05 | Philips Electronics N.V. | A spread-spectrum based cellular mobile radio system, and a control arrangement, a radio base station, and a mobile radio station |
Non-Patent Citations (1)
Title |
---|
See also references of EP0900791A4 * |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6426413B1 (en) | 1998-03-09 | 2002-07-30 | Vertex Pharmaceuticals Incorporated | Inhibitors of caspases |
US8691848B2 (en) | 1998-03-19 | 2014-04-08 | Vertex Pharmaceuticals Incorporated | Inhibitors of caspases |
US6531474B1 (en) | 1998-03-19 | 2003-03-11 | Vertex Pharmaceuticals Incorporated | Inhibitors of caspases |
US7358273B2 (en) | 1998-03-19 | 2008-04-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of caspases |
JP2002527510A (ja) * | 1998-10-16 | 2002-08-27 | アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | インターロイキン−1−βインヒビターとしての置換されたチアジアゾールスルホンアミド |
JP4733270B2 (ja) * | 1998-10-16 | 2011-07-27 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | インターロイキン−1−βインヒビターとしての置換されたチアジアゾールスルホンアミド |
US6762198B2 (en) | 1999-03-03 | 2004-07-13 | The Procter & Gamble Company | Dihetero-substituted metalloprotease inhibitors |
US6197770B1 (en) | 1999-03-03 | 2001-03-06 | The Procter & Gamble Co. | Alkenyl- and alkynl-containing metalloprotease inhibitors |
US8071551B2 (en) | 1999-03-05 | 2011-12-06 | BioHolding, Inc. | Methods and compositions for treating diabetes |
US7704958B1 (en) | 1999-03-05 | 2010-04-27 | Bio Holding, Inc. | Methods and compositions for inhibiting apoptosis using serine protease inhibitors |
US6489308B1 (en) | 1999-03-05 | 2002-12-03 | Trustees Of University Of Technology Corporation | Inhibitors of serine protease activity, methods and compositions for treatment of nitric-oxide-induced clinical conditions |
US6981659B1 (en) | 1999-05-06 | 2006-01-03 | Gordon Duane Hopkins | Liquid mist fire extinguisher |
WO2001068655A2 (en) * | 2000-03-10 | 2001-09-20 | Ariad Pharmaceuticals, Inc. | Caprolactam derivatives and uses thereof |
WO2001068655A3 (en) * | 2000-03-10 | 2002-08-01 | Ariad Pharma Inc | Caprolactam derivatives and uses thereof |
EP1923386A2 (en) | 2000-03-29 | 2008-05-21 | Vertex Pharmceuticals Incorporated | Carbamate caspase inhibitors and uses thereof |
US7074782B2 (en) | 2000-03-29 | 2006-07-11 | Vertex Pharmaceuticals Incorporated | Carbamate caspase inhibitors and uses thereof |
US9156880B2 (en) | 2000-05-19 | 2015-10-13 | Vertex Pharmaceuticals Incorporated | Prodrug of an ice inhibitor |
US9994613B2 (en) | 2000-05-19 | 2018-06-12 | Vertex Pharmaceuticals Incorporated | Prodrug of an ICE inhibitor |
US9487555B2 (en) | 2000-05-19 | 2016-11-08 | Vertex Pharmaceuticals Incorporated | Prodrug of an ice inhibitor |
US8329662B2 (en) | 2000-05-19 | 2012-12-11 | Vertexd Pharmaceuticals Incorporated | Prodrug of an ICE inhibitor |
JP2003534325A (ja) * | 2000-05-23 | 2003-11-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | カスパーゼインヒビター及びその使用 |
US7858776B2 (en) | 2002-10-03 | 2010-12-28 | Astrazeneca Ab | Lactams and uses thereof |
WO2004080983A1 (en) * | 2003-03-14 | 2004-09-23 | Astrazeneca Ab | Novel lactams and uses thereof |
US7342007B2 (en) | 2003-03-14 | 2008-03-11 | Astrazeneca Ab | Lactams and uses thereof |
EP2520654A1 (en) | 2003-08-26 | 2012-11-07 | The Regents of the University of Colorado | Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections |
EP3192872A1 (en) | 2003-08-26 | 2017-07-19 | The Regents of the University of Colorado, a body corporate | Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections |
Also Published As
Publication number | Publication date |
---|---|
EP0900791A1 (en) | 1999-03-10 |
KR19990076818A (ja) | 1999-10-15 |
EP0900791A4 (ja) | 1999-03-10 |
US6376484B1 (en) | 2002-04-23 |
US6136834A (en) | 2000-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997024339A1 (fr) | Derives de tetrazole et medicaments les contenant a titre d'ingredients actifs | |
CN100545160C (zh) | 二胺衍生物 | |
EP0761680A2 (en) | Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity | |
CN1826333B (zh) | 二胺衍生物 | |
WO1999019296A1 (fr) | Derives d'acide aminobutanoique | |
EP1612208B1 (en) | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | |
EA020580B1 (ru) | Макроциклические ингибиторы сериновых протеаз гепатита с | |
HUT56095A (en) | Process for producing benzopyrane derivatives and pharmaceutical compositions containing them | |
US6900207B2 (en) | N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient | |
WO2003070707A1 (fr) | Composes condenses derives de la pyridazine et medicaments contenant lesdits composes comme ingredients actifs | |
WO1998018794A1 (fr) | Nouveaux composes d'amide heterocycliques et leur utilisation a des fins medicinales | |
WO2004058715A1 (ja) | ジアミン誘導体 | |
EP2009004A1 (en) | Novel piperazine compound, and use thereof as hcv polymerase inhibitor | |
WO1999051587A1 (fr) | Derives de thiophene condenses et medicaments contenant ceux-ci comme principe actif | |
EP0182301B1 (en) | 3-substituted carbacephem and cephem compounds and pharmaceutical compositions | |
WO2023044171A1 (en) | Inhibitors of cysteine proteases and methods of use thereof | |
WO2001044214A1 (fr) | Derives d'oxadiazole et medicaments contenant ces derives utiles comme ingredients actifs | |
WO2004058728A1 (ja) | 新規なエチレンジアミン誘導体 | |
RU2304438C2 (ru) | Бензотриазепины в качестве лигандов рецепторов гастрина и холецистокинина | |
WO2002096892A1 (fr) | Composes derives d'oxadiazole et medicaments contenant ces composes comme ingredient actif | |
CA2979926A1 (en) | Substituted n-bicyclo-2-aryl-quinolin-4-carboxamides and use thereof | |
JP2003523337A (ja) | マトリックスメタロプロタアーゼ阻害剤としてのチアゼピニルヒドロキサム酸誘導体 | |
WO2001055118A1 (fr) | Derives heterocycliques condenses au benzene et medicaments contenant ceux-ci comme ingredients actifs | |
WO2001040204A1 (fr) | Derives de 1.3.4-oxadiazoline et medicaments contenant ces derives utiles comme ingredients actifs | |
CN1751025B (zh) | 二胺衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WR | Later publication of a revised version of an international search report | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1019980704944 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09101004 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996942651 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1996942651 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019980704944 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996942651 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019980704944 Country of ref document: KR |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) |